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Witness seMinArs: 
MEETINGS AND PUBLICATIONS 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000 to 30 September 
2010. The History of Twentieth Century Medicine Group has been part of the 
School of History, Queen Mary, University of London, since October 2010, as 
the History of Modern Biomedicine Research Group, which the Wellcome Trust 
continues to fund.
The Witness Seminar is a particularly specialized form of oral history, where several 
people associated with a particular set of circumstances or events are invited to 
come together to discuss, debate, and agree or disagree about their memories. To 
date, the History of Twentieth Century Medicine Group has held more than 50 
meetings, most of which have been published, as listed on pages pages xiii–xvii. 
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been agreed, 
suitable participants are identified and invited. This inevitably leads to further 
contacts, and more suggestions of people to invite. As the organization of the 
meeting progresses, a flexible outline plan for the meeting is devised, usually with 
assistance from the meeting’s chairman, and some participants are invited to ‘set 
the ball rolling’ on particular themes, by speaking for a short period to initiate and 
stimulate further discussion.
1  The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine as listed on pages xiii–xvii.
xEach meeting is fully recorded, the tapes are transcribed and the unedited transcript 
is immediately sent to every participant. Each is asked to check his or her own 
contributions and to provide brief biographical details. The editors turn the 
transcript into readable text, and participants’ minor corrections and comments 
are incorporated into that text, while biographical and bibliographical details are 
added as footnotes, as are more substantial comments and additional material 
provided by participants. The final scripts are then sent to every contributor, 
accompanied by forms assigning copyright to the Wellcome Trust. Copies of all 
additional correspondence received during the editorial process are deposited 
with the records of each meeting in archives and manuscripts, Wellcome Library, 
London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
xi
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introduCtion
Those of us concerned with medical and biological research (and its funding) 
need to consider many factors: a long memory, a conscience, willingness to 
work round mindless rules and regulations, and a disdain for action that is not 
backed by evidence. Some are occasionally ignored. The Avon Longitudinal 
Study of Pregnancy and Childhood (now known as The Avon Longitudinal 
Study of Parents and Children) – ALSPAC – illustrates these points to a nicety.
The lament for the days when research was one man (usually a man) and his 
ideas, alone in his clinic or laboratory, is almost silent. It is even less likely, 
one might argue, that a major epidemiological study could be born from the 
ideas and drive of one person. ALSPAC is the counter-argument. Those with 
the aforementioned long memory, who can recall Jean Golding’s determined 
advocacy of ALSPAC some 30 years ago, will agree that the impelling force of 
one well-prepared and well-informed individual was essential for the inception, 
growth and long life of the project. That drive and determination is well 
recognised by the participants at this seminar.
Should this account trouble our consciences? One reason why it might is 
eloquently described by participants in the seminar. Once the scientific merit 
of ALSPAC had been agreed after careful peer review, why was it so difficult 
for the essential infrastructure to be created? Why did funding agencies persist 
in the style of Procrustes, attempting to fit the funding of ALSPAC into the 
project grant model? Nevertheless, the fact is that funding was found. The 
Wellcome Trust, to its great credit, recognized the strength of the scientific case 
made by Jean Golding, and provided her personal support for many years, at a 
time when the Trust was much less wealthy than it is now. An increase in the 
resources of the Trust allowed more complete funding, including support for 
the infrastructure.
The moral that emerges for the funder is that if a piece of research deserves 
financial support, and if the funder has enough money, then a form of funding 
must be found – or created – to deliver that funding. Persuading other funding 
agencies to provide infrastructure or other core funding should, for the 
researcher, not be a distraction from the struggle to ensure that good work gets 
done. In the case of ALSPAC, only the vision of the leaders of the University of 
Bristol, and the strong nerves of its finance department, kept the project alive.1
1 See comments by Professor Brian Pickering and Professor Gordon Stirrat on pages 18–19.
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Even when it has been carefully designed, research often develops in unplanned 
ways. One of the plans for ALSPAC, from the start, was to collect biological 
samples, which was unusual in large cohort studies at that time. Meticulous 
attention to sample collection, documentation and storage, and the linkage to 
other survey data, questionnaires and so on, has created a treasure trove for 
research both now and in the future. But who could have predicted that genetic 
information, rather than biological or biochemical data, would be the main 
achievement to date? These achievements in genetics from ALSPAC epitomise 
the current weakness in matching biological understanding to the cornucopia 
of genetic information, a challenge for twenty-first century biological science.
To return to the opening list of precepts, there is the question of rules and regulations, 
some of which certainly appear mindless. Again, long memories will recall a time 
when patients and populations in research were protected mainly by the conscience 
and professional standards of the scientist or doctor conducting research and by the 
common law of tort. Are we really better off for the regulations that now surround 
us, on, for example, consent?2 It certainly is not logical for large-scale clinical trials 
or cohort studies, with a single precise protocol, to be seen by multiple ethics 
committees, and sometimes to face different requirements in different places.3 
Research ethics is not a matter that should have geographical variation within one 
country. ALSPAC led rather than followed here: its Ethics Committee was set up 
very early in the project, and promoted the intelligent development of the legal 
and ethics framework of the study.4 The regulations and procedures for gaining 
ethics approval for large-scale epidemiological research must be clear and consistent. 
Similarly, the rules for the use of National Health Service facilities for clinical and 
epidemiological research (for example, for support from the National Institute for 
Health Research Clinical Research Network5) must be clear and appropriate. As I 
have argued before, the NHS – “…a population-wide, comprehensive healthcare 
system, free to the patient at the point of consultation, and able to support the 
clinical infrastructure of research…”6 is a research resource almost without rival, 
worldwide, and must remain open and accessible to good quality epidemiological 
and clinical studies.
2 See comments by Professor Catherine Peckham on page 49.
3 See comments by Professor George Davey Smith on pages 75–6.
4 See comments by Mrs Elizabeth Mumford on pages 71–5.
5 http://www.crncc.nihr.ac.uk/about_us/processes/portfolio (visited 16 April 2012).
6 http://www.history.qmul.ac.uk/research/modbiomed/Publications/wit_vols/44829.pdf page i (visited 
16 April 2012).
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ALSPAC has implications for the funding, and for the regulatory framework of 
other major epidemiological studies. It sits alongside other pioneering population 
studies, such as the National Perinatal Mortality Surveys,7 and shows that the field 
remains open for well-planned studies, often to answer specific hypotheses, but 
also with the potential to unlock important new and unexpected information. 
ALSPAC has created data that provides sound evidence for our understanding 
of child development. As the evidence supporting science and medicine grows, 
should not associated decisions be equally based on strong evidence? What, for 
example, is the economic, social and epidemiological evidence that supports 
successive reorganizations of health care systems? Are the changes introduced to 
medical education always based on reasonable evidence, rather than guesswork? 
Medicine, biomedical science, or medical education should never become like 
climate science, distorted by ideological argument: evidence matters.
ALSPAC has handsomely rewarded those who had the vision to create the 
project, and to provide the funding, and has given us solid new scientific 
information. This Witness Seminar tells its story, so far.
david gordon 
World Federation for Medical Education
7 See http://cls.ioe.ac.uk/page.aspx?&sitesectionid=736&sitesectiontitle=Perinatal+Mortality+Survey+(1958 
(visited 16 April, 2012).
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Professor tilli tansey: Ladies and gentlemen, I’d like to begin by welcoming 
you all to this Witness Seminar on ALSPAC.1 I’m the convenor of the History 
of Modern Biomedicine Research Group; and in the mid-1990s we started 
Witness Seminars to get together historians, scientists and clinicians who are 
interested in the history of medicine, as a way of getting to know each other 
but also to generate material resources in modern medical science and modern 
medical practice. We conduct a variety of meetings and you will see flyers of our 
meetings with the list of everything we’ve ever done. We transcribe and edit the 
proceedings of all our meetings. Everything is freely available on the web, and 
is downloadable. Nothing will be published from this meeting without your 
express written permission.
The subject of ALSPAC, the Avon Longitudinal Study of Parents and Children, 
was first mentioned to me as a possible Witness Seminar by Marcus Pembrey 
and Jean Golding several years ago, and it has taken some while to try to work 
out how and when to do it. We’re delighted that we are finally holding it 
and, of course, a key person in any of these meetings is the chairman. We’re 
particularly pleased that Catherine Peckham has agreed to chair this meeting. 
She’s professor of paediatric epidemiology at the Institute of Child Health, and 
she is best known for her work on infections in pregnancy, particularly rubella, 
cytomegalovirus and HIV, and their impact on the fetus and development of 
the child. She showed that congenital rubella damage caused by exposure to 
maternal infection in pregnancy could continue after birth.2 She’s worked a lot 
on national cohort studies and therefore she’s an absolutely ideal person to chair 
our meeting on ALSPAC; and without further ado I’ll hand over to Catherine. 
Professor Catherine Peckham: This is the first time I’ve experienced one of 
these Witness Seminars and it is like going back down memory lane. I remember 
that I first met Jean Golding in the 1960s when I was working on the 1958 
cohort,3 and working on cohorts in those days was considered very non-medical. 
You had to have a foot in the medical environment to be doing real research, 
and the cohorts were regarded as rather descriptive social research with little 
1 The Avon Longitudinal Study of Parents and Children (also known as Children of the 90s). Until 1999 
ALSPAC referred to the Avon Longitudinal Study of Pregnancy and Childhood. 
2 See note 4.
3 The 1958 Birth Cohort or the National Child Development Study (NCDS) was initially designed 
to examine perinatal mortality among the children born in Great Britain in one week in March 1958. 
Although not designed as a longitudinal survey, a large proportion of the cohort has been followed since 
then. See Peckham (1973); Power and Elliott (2006) and Welshman (2012). See also Appendix 1.
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000
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relevance for medicine. However we all knew they were useful and important. 
My particular area of research was in infections in pregnancy, especially the 
adverse effects of infections in pregnancy on the child,4 both in the near term 
and long term, and to me birth cohort studies were incredibly important. So 
it was a pleasure to have met people like Jean Golding. The analysis of data 
from these studies was then quite basic because we hadn’t the technology that 
enabled us to do sophisticated analyses; a lot was done with counter sorters, 
and by hand, and it’s been interesting looking at the evolution of these studies 
over time. That takes me to a discussion that I had at a meeting organized by 
Iain Chalmers in Oxford.5 I’m sure you’ll remember it, Jean. You talked to me 
about the need for a new cohort; the need to move from the birth of the child 
to understand more about what was going on in pregnancy. I thought this was 
a great idea because I had always been interested in events in pregnancy, and I 
was concerned we were relying on memory or recorded events or interventions 
in pregnancy, and not acquiring the necessary detailed information. It was 
an era when trials were everything: people wanted to do things scientifically, 
and cohort studies were not then regarded as scientific. We had an interesting 
discussion and I encouraged Jean to ‘go for it!’ I thought it was important and 
she had the necessary passion and energy. I think it’s extraordinary that one 
person was able to fight against the system and be so far advanced in thinking 
about the issues. 
4 See, for example, Peckham (1972); Peckham et al. (1983, 1988). 
5 Sir Iain Chalmers directed the National Perinatal Epidemiology Unit in Oxford between 1978 and 1992. 
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I would like you to try to recall that meeting in Oxford, Jean, and to ask you to 
rehearse what you think the objectives were and why you thought this new study 
would progress the whole cohort development; how you justified it being local, 
not national, because people would say you can’t extrapolate the findings to the 
general population. I’d like you to start there, telling us what your thoughts 
were; what was going on within the medical fraternity at the time – genetics 
wasn’t the key issue – we were in an era when people were beginning to talk 
about the importance of early life on later health; people were talking a great 
deal about immunology. Can you tell us about the beginning and your ideas at 
that time? 
Professor Jean golding: Well, certainly the beginning for me was when I 
fortuitously started working with big, national cohort studies. So I’d worked on 
the 1958 cohort study6 and fell in love with the methodology, and in particular, 
looking at things like congenital malformations, which I thought were fascinating, 
although not many other people did. And then when there was an opportunity, 
I was invited by Iain Chalmers to design a new national cohort study, and so 
I did a lot of thinking, talking to experts in various fields and came up with 
a design that involved enrolling mothers in pregnancy. Well, if you’re doing a 
study nationally, enrolling in pregnancy and having a defined cohort is pretty 
difficult. But we decided it was do-able by enrolling a lot more people than 
you’d actually end up studying. So you’d get information on pregnancies in huge 
numbers. I’ve just been reading the document I produced, which I haven’t read 
since 1980 and I was going for 50 000 deliveries to be followed up, plus some 
samples of different sorts, which perhaps rightly, was turned down out of hand.7 
But it had meant that I’d thought through the importance of pregnancy and 
thought through the importance of following up in detail, particularly looking 
at environmental factors in pregnancy, which had been very much ignored, other 
than smoking.8 As things developed it was the importance of including biological 
samples that came to the fore as one of the ways of measuring environments that 
you couldn’t measure in other ways. The next phase in all this, by which time I 
was in Bristol,9 I was invited by WHO to a meeting in Moscow in 1985, which 
6 See note 3.
7 Professor Jean Golding wrote: ‘This was turned down by the Department of Health who had 
commissioned me to design and cost the study.’ E-mail to Ms Caroline Overy, 18 December 2011.
8 For the adverse effects of smoking in pregnancy see, for example, Simpson (1957); McIntosh (1984); 
Kleinman et al. (1988). 
9 Professor Jean Golding went to Bristol in 1980.
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had a very vague remit but it was basically to design a study.10 Because I was the 
only native English-speaker, I was the rapporteur. After talking round in circles 
for two or three days, I decided I would write what I thought they ought to 
have decided, rather than what they didn’t decide, and presented that the next 
day. They all were enthusiastic, and so we developed it from there. I was slightly 
devious there, but [laughs] open in the end. 
What we ended up with was the design of a cohort study which started in 
pregnancy and followed children through, long term. And because there was 
a very loquacious Greek psychologist there, there was a big emphasis on the 
psychology and the importance of measuring the psychology of the parents, and 
the way they interacted and the way they would interact with the child, and the 
child’s behaviour.11 So that helped formulate the design a lot. WHO, and this 
was only WHO EURO, so it was only the European countries,12 decided that 
this warranted some piloting, so it gave me US $5000 to pilot, in Greece and 
Russia and the UK, to see whether one could collect accurate information using 
self-completed questionnaires. That was thought not to be the sort of thing that 
one did, you know, you wouldn’t get accurate answers, you had to have trained 
interviewers. So we did pilot studies and compared results with things that we 
could validate to show what would work and what wouldn’t work.13 Well, we 
showed that it would be difficult to do it in Greece because we put the Eysenck 
psychology scale in there and that includes a lie scale, and they were scoring very 
high on the lie scale.14 In other words, they were giving us the answers they thought 
we wanted. [Laughs] So that wasn’t very good. The others, Russia and England, 
10 Professor Jean Golding wrote: ‘WHO’s remit was that the study should be undertaken across Europe 
with the aim of concentrating on the health of children.’ E-mail to Ms Caroline Overy, 18 December 2011.
11 Professor Jean Golding wrote: ‘The psychologist was Thalia Dragonas, based in Athens at the Foundation 
for Research in Childhood. She is now a professor at the department of early childhood education at the 
University of Athens.’ E-mail to Ms Caroline Overy, 18 December 2011. Dragonas’ research focuses on 
psychological and social identities.
12 In 1985 WHO EURO comprised: Albania, Austria, Belgium, Bulgaria, Czechoslovakia, Denmark, Finland, 
France, German Democratic Republic, Federal Republic of Germany, Greece, Hungary, Iceland, Ireland, Italy, 
Luxembourg, Malta, Monaco, Morocco, Netherlands, Norway, Poland, Portugal, Romania, San Marino, 
Spain, Sweden, Switzerland, Turkey, USSR, United Kingdom and Yugoslavia; see Grant (1985): i. 
13 Some of the pilot studies comparing Greece and the UK were published in Dragonas et al. (1992); 
Thorpe et al. (1992a and b).
14 Professor Hans Jürgen Eysenck (1916–1997), a German-British psychologist who worked on intelligence 
and behaviour theory. For his psychology scale, see Eysenck and Eysenck (1975).
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were fine on that. The Russians, however, didn’t like the questions that had more 
than a yes/no answer; they really didn’t like gradations of grey, whereas the Brits 
did want that. There were various technicalities that one had to sort out in order 
to get something that could be used in different countries. But WHO at that 
point decided that we could progress and they wrote to every health department 
in Europe saying there was this study, and they would encourage them to take 
part, what the rules of the study were, that there would be a core of information 
to be collected, and then each country could add whatever they wanted to that 
core.15 The countries that had a private health service really found it very difficult 
to even think about this, and largely didn’t take part.16 The countries that said ‘yes’ 
were mainly in the old Eastern bloc, who just put it in their five-year plan; funding 
wasn’t an issue; they had people employed, they had to keep doing something. 
That was fine but our timing was all wrong, perestroika17 happened very rapidly, 
and people unexpectedly had to raise their own funds for the research. But some 
countries are still carrying on with that study.18 What none of them wanted to do 
was collect biological samples,19 which we decided was very important, and so the 
Avon side of ELSPAC,20 which is known as ALSPAC, expanded the basic data 
to be collected to include biological samples, not so much because of genetics, 
although by the time we started I’d met Marcus Pembrey, but so that we could 
look at things that you couldn’t get from questionnaires, so that included features 
of the environment, and things like infections and immunology. So that’s the way 
it began. There were lots of different aspects to this. One of the things WHO 
had said in this letter that went to all the Ministries of Health, was that WHO 
wouldn’t contribute any funding except something towards a meeting of directors 
15 The study was called ELSPAC – the European Longitudinal Study of Pregnancy and Childhood. It 
comprised over 40 000 children and their families followed in Great Britain, Isle of Man, the Czech 
Republic, Slovakia, Russia, Ukraine, and initially in Greece and Spain. See Golding (1989a).
16 Professor Jean Golding wrote: ‘This is why Greece had to drop out and countries such as Belgium and 
France declined to join.’ E-mail to Ms Caroline Overy, 18 December 2011.
17 Perestroika was the policy of political, economic and social restructuring in the Soviet Union, instituted 
by Mikhail Gorbachev in the mid-1980s. 
18 Ukraine, Czech Republic, Slovakia and Great Britain (as ALSPAC) and the Isle of Man.
19 Professor Jean Golding wrote: ‘This was partly for ethical reasons, but also a question of resources required 
to both collect and process and store such samples.’ E-mail to Ms Caroline Overy, 18 December 2011.
20 Professor Jean Golding wrote: ‘There was an Avon side because I was based in Bristol which is the centre 
of what was the Avon area.’ E-mail to Ms Caroline Overy, 18 December 2011. 
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of the study annually, which fizzled out quite soon.21 The people who wanted to 
take part did get more and more enthusiastic about the whole thing, and I think 
a lot of chance events helped take it forward. 
I’m sure Marcus will tell you how we met, which was totally unplanned. I 
was fortunate in that, in Bristol, two of my old colleagues from Oxford were 
appointed, so Gordon Stirrat came very soon after I did, and David Baum 
was then appointed as professor of child health, and Neville Butler retired.22 
The input from those three was extremely important at various times. Other 
contributions from around the country were important in making sure that 
we’d honed our ideas, because we were challenged at all points, I think, not 
only in the overall design of doing everything. My argument is: ‘You can’t look 
at one thing without taking account of all these other things, and how are 
you going to find out anything new anyway unless you study it?’ This is what 
clinicians do: noticing who comes into their consulting rooms; they realize 
they’ve all got blue eyes or whatever, so… discoveries are not always made 
with a prior hypothesis. That didn’t go down terribly well. [Laughs] But, now, 
in the days in which a genome-wide association study (GWAS)23 works and 
genetic analyses are done, which are totally hypothesis-free, I think it has been 
recognized more and more that this is a viable way of doing things. So that’s 
the way in which we planned it. 
Peckham: Would anyone like to come in on that? Gordon, would you? You 
were involved very much in the early days in Bristol.
Professor gordon stirrat: Yes, I was involved from the very beginning. I had 
been a clinical reader in obstetrics and gynaecology in the University of Oxford 
when Jean was there, and was involved in her work. I was very interested in 
the work she was doing in, for example, record linkage studies etc. When I 
moved to Bristol, my research area was fetal development and feto-maternal 
21 Professor Jean Golding wrote: ‘These meetings fizzled out at the point at which our main supporter in 
WHO EURO, Dr Prokorskas, changed position and his successors were not interested or committed to the 
study.’ E-mail to Ms Caroline Overy, 18 December 2011.
22 Professor Gordon Stirrat was appointed professor and head of department of obstetrics & gynaecology 
in the University of Bristol in 1982; Professor Neville Butler (1920–2007) was professor of child health, 
University of Bristol, from 1965 until 1985, and was succeeded by Professor David Baum (1940–99) who 
had been clinical reader in paediatrics at the University of Oxford.
23 Genome-wide association studies (GWAS) are used to identify common genetic factors that influence 
health and disease. See, for example, Hardy and Singleton (2009) and also the factsheet on the website of the 
National Human Genome Research Institute at www.genome.gov/20019523 (visited 14 November 2011). 
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relations,24 and it seemed to me that a study of pregnancy, which I thought 
was an extremely important part of the ultimate development of the child, was 
being neglected, because people measured the first day of life as being birth. I 
knew very well there was actually an awful lot that went on in utero, including 
environmental aspects and as a result of infection. This was music to my ears 
and I was really very strongly supportive. 
There was a very interesting episode that occurred, and Jean didn’t know about 
this until yesterday. Given that WHO were not going to be providing funds, 
and of course the imperative was to get funds, Neville Butler approached the 
Wellcome Trust and Medical Research Council (MRC). He was told by the 
Wellcome Trust that, yes, the idea was good but, since he was going to be 
retiring within a relatively short time (he retired in 1985, so this must have 
been some time in 1983/4), they didn’t feel they could support the project 
unless it was backed by another department in the University of Bristol, where 
the head of that department was not going to be retiring as soon as Neville 
was. So he approached me about that and I came with him to the Wellcome 
Trust and we had a discussion with them. The funding was given on the basis 
of it being jointly held by the two departments, and I feel very proud that I 
was able to facilitate this funding. Interestingly enough, Neville managed to 
keep that rather quiet, but we won’t say any more about that. However, these 
arrangements led to real problems with David Baum, Neville’s successor, because 
he had not been given this information. It was great to have David Baum in 
Bristol and the situation was sorted out and wasn’t a lasting problem.25 From 
my point of view, I was very privileged to be a facilitator of the project, and feel 
that perhaps there was something I contributed that was crucial; but then, of 
course, the whole collection of data right from the beginning of pregnancy was 
right up my street. However, it was not without its problems by any means. 
One of the things I was really excited about, and perhaps will talk about that 
later, was the collection of placentas,26 because we tend to throw placentas out; 
we think they’re just ‘baggage’, whereas other cultures have very different ideas 
24 See, for example, Sunderland et al. (1981); Sargent et al. (1982).
25 Professor Gordon Stirrat wrote: ‘In subsequent discussion it became clear that this episode related to a bid 
for a Wellcome Senior Lectureship for Jean and not the ALSPAC project per se’. Note on draft transcript, 
6 September 2011. Professor Jean Golding also wrote of this episode: ‘Much of it is true but is related to a 
different piece of research, not ALSPAC.’ Note on draft transcript, 3 October 2011.
26 The terms ‘placentas’ and ‘placentae’ were both used during the Witness Seminar. For consistency in this 
transcript, we have used the term ‘placentas’.
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about what the placenta is.27 For example, the Greeks called the placenta and 
the membranes deutera while the Romans called them the secundinae, both of 
which mean the ‘second born’. There’s still a huge amount of information in 
a warehouse somewhere incarcerated within the placentas which are still kept, 
which I think could add to the study even now.28 
Peckham: What was the funding from the Wellcome for? Was that for Jean’s 
fellowship or salary? It wasn’t for the study, was it?
golding: No, it wasn’t for the study.29 It was for a research assistant or research 
fellow working with me, who was Jon Pollock, and a secretary. As it was, they 
demanded that the university took over my funding; I’m sure it was Brian 
Pickering who had to negotiate with the Wellcome Trust at the time. 
Peckham: So that was a pretty pivotal moment?
golding: Yes.
Peckham: Does anyone else want to say anything else about those early days? 
You were going to say something, George, about a note. Do you want to read 
it out? I think it’s interesting. I don’t know how it relates to the timing, but I 
imagine it was quite early on.
Professor george davey smith: Yes, this was earlier than Jean and I 
remembered, so it took me a while to find this. It was in the News and Notes 
section of the Lancet, 26 August 1989,30 in the days when people used to read 
journals. I obviously had nothing better to do than to read the News and Notes 
in the Lancet. It said:
Study on factors influencing child health
A Longitudinal Study of Pregnancy and Childhood (ALSPAC) is being 
planned by the University of Bristol and is due to start in 11 months’ 
time. The aim is to determine which biological, environmental, social, 
genetic, psychological, and psychosocial factors are associated with the 
27 See, for example, Birdsong (1998).
28 Professor Jean Golding wrote: ‘As so often in this study, data and samples were collected and little interest 
was taken in them for many years. In the case of the placentas, it was not until 2010 – then two different 
research groups obtained funding to look at the placentas in some detail.’ E-mail to Ms Caroline Overy, 24 
February 2012.
29 See note 25. 
30 Anon. (1989).
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survival and health of the fetus, infant and child. The cohort will consist 
of all births in the three Avon health districts over a 12-month period, 
and women and their partners will be recruited to the study as soon 
as possible after confirmation of pregnancy. Collaboration with other 
research groups or individuals is being sought. Potential collaborators 
should contact Dr Jean Golding, Division of Epidemiology, Institute of 
Child Health … Bristol.’ 
Peckham: And what date was that?
davey smith: 26 August 1989. 
Peckham: 1989. Had you funding by then? [Laughter] 
Professor Marcus Pembrey: Because we’ve got to 1989 I thought I’d better chip 
in as to when I first met Jean. In January 1988 there was a meeting on child 
development in Athens, and I was asked to talk about genetic prediction and 
so on, and Jean was talking on some other subject there.31 We met and she said 
‘Oh, I’ve got this study that I’m quite interested in’ and within two weeks, I see 
from my old work diaries that have been kept, Jean had come to visit me on 5 
February. I remember that meeting very well. She asked if I would be interested 
and prepared to help, and I know that there is a letter that I then sent saying: 
‘I’m very happy to help where I can but I can’t commit very much time, but 
I’ll do what I can.’ And, of course, within about two months it was taking up 
about 50 per cent of my academic work. But I’ll come back to the genetics of 
it at a later stage.32 
Professor Alan emond: In 1985 I was appointed as lecturer. I arrived at the 
same time as David Baum, and I distinctly remember in the beginning of 1986, 
Jean summoning me to her office. I was very much the young lecturer; I had just 
finished my doctorate and I was looking for my first post-doc study. Jean called 
me in and I felt a bit nervous because I wasn’t sure what it was about. [Laughter] 
She said: ‘Oh, I’ve got this new project, this new cohort study that I’m going 
to launch. I’ve just come back.’ She told me about the meeting in Moscow, 
and said: ‘I want a keen paediatrician to help run it.’ I thought that I fitted 
that category, and offered to be the paediatric link for the burgeoning design 
of the study. This was actually very timely for me, because I was launching a 
31 NATO Advanced Research Workshop on Early Influences Shaping the Individual, 20–24 January 1988, 
Athens, Greece. The proceedings of this meeting were published in Doxiadis (ed.) (1989). Papers include 
Pembrey (1989) and Golding (1989b).
32 See page 57 onwards. 
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small follow-up study of preterm infants, the Avon Preterm Follow-up Study.33 
In that study we looked at a cohort of preterm babies in the community so we 
were able to pilot a lot of the questionnaires, which were used in pregnancy in 
ALSPAC. Through Jean’s help, we received a small amount of funding from 
the Department of the Environment, who were particularly interested in the 
environmental effects on babies’ health. We used the same methodology, self-
completion questionnaires, to capture environmental information and then we 
linked that to health outcomes in these babies. A lot of the environmental aspects 
in the ALSPAC questionnaires were piloted as part of that study. I can honestly 
say I was the first paediatrician to be involved and I went around proselytizing 
the value of longitudinal studies, because previously, for my doctorate, I worked 
with the MRC Sickle Cell Unit in Jamaica with Graham Serjeant and had been 
completely convinced about the value of longitudinal studies.34 So I brought 
that experience and that enthusiasm with me to the beginning of ALSPAC.
Peckham: The drawing together of interested individuals has obviously been very 
important. Before you even got the funding and were launching the project, it 
became a reality. It’s interesting that the emphasis on the external environment 
was a key justification for taking the samples. This was so different from the 
earlier cohorts in that an attempt was being made to measure environmental 
exposure. This made it novel. How did you, Jean, justify restricting the study 
to a local level, countering the argument that it should be national? Was that a 
problem?
golding: I didn’t think it was a problem. I think it’s only a problem if you 
consider the survey as something that is going to give you the prevalence within 
a country. But the value of longitudinal surveys is in the longitudinal nature of 
them, so it shouldn’t matter so much that this is only taking place in one area; it 
might not have environments that you are interested in, but it does have a lot of 
environments you can look at longitudinally to see what the effects are. I think 
that is an advantage rather than a disadvantage, because you can actually get a 
handle on what those environments are. You can go out and sample, whereas 
that would be much more difficult to do nationally. That’s the sort of thing we 
did with a number of different environments that we were measuring like the 
33 The Avon Preterm Follow-up Study investigated the interaction of environmental and medical factors on 
the health of preterm infants, less than 32 weeks’ gestation, born in Avon between 1 October 1987 and 30 
November 1988; see Emond et al. (1997).
34 Emond (1987). Dr Graham Serjeant was then the director of the MRC Laboratories (Jamaica) which 
operated the Sickle Cell Unit at the University of the West Indies, Kingston, Jamaica; he retired in 1999.
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electric magnetic radiation, or air pollutants.35 That’s one argument for having 
it local, but the major advantage, I think, is that locally you can get your local 
media and all the local health professionals to become part of the study, to be 
interested in it and want to know what the latest results are. Nearly everybody 
who’s lived in Bristol or the surrounding area knows somebody who’s in the 
study. It’s very unusual for me to meet somebody who doesn’t tell me about 
their cousin or their nephew or a friend who is part of the study. I think that 
sort of drawing together of the community couldn’t happen with a national 
study. They don’t know one another, whereas here you have whole classes at 
school where nearly everybody in the class is part of the study, and those who 
aren’t feel very jealous of those who are, which keeps the whole thing rolling 
along. So, there are major advantages to having it in one area.36 
Peckham: It is very helpful to hear the case for the local study and local 
ownership. This has important implications for governance, which we’ll talk 
about later. 
golding: One other thing about being local is the examination of children. You 
can do it under situations that you have control of. For example, if you’re doing 
something simple like taking the blood pressure of children around the country, 
such as happened in the 1970 cohort, we had geographic differences between 
areas but didn’t know if they were real geographic differences or differences 
between the people measuring the blood pressure.37 We never sorted that one 
out, whereas in this case we can keep hands on and keep that aspect under 
control.
Peckham: Does anyone want to add anything at this point? 
dr Jon Pollock: I want to emphasize two scientific components of the origins 
of this study, which were very impressive for me in relation to the British birth 
cohort studies that had gone before, which many of us had worked on.38 And 
that was Jean explaining to me, and me being convinced by, the argument that 
35 Preece et al. (1999); Sherriff et al. (2005). 
36 For a discussion of the use of a local rather than national sample, see Golding (2009).
37 The 1970 British Cohort Study (BCS70) is an ongoing longitudinal study, which started by collecting 
data about the births and families of just under 17 200 babies born in the UK in one particular week 
in April 1970; see http://cls.ioe.ac.uk/page.aspx?&sitesectionid=795&sitesectiontitle=Welcome+to+the+ 
1970+British+Cohort+Study (visited 31 January 2012). See also Elliott and Shepherd (2006).
38 See notes 3 and 37. 
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longitudinal studies should be planned as longitudinal studies and the idea 
of funding a study to be longitudinal. Of course, the earlier national cohort 
studies were not longitudinal; they were cross-sectional studies that became 
longitudinal.39 That’s a much easier arrangement to have managerially, but, of 
course, it means that you’re not necessarily collecting the right information at 
the right time, particularly in relation to measuring exposures close to the time 
of exposure, as opposed to retrospective recall of data, which is what largely they 
depend on.40 That’s one issue which, I think, makes this study unique, or rare, 
in the scientific literature. The other is an issue that you skated over, Jean, but I 
think we’re going to have to come back to it, is the business of this not being a 
hypothesis-generated study. This was seen at the time to be a serious weakness of 
the study, particularly in relation to funding opportunities, of course. There are 
lots of good reasons for that, but, as time will tell, as things will happen, as the 
information emerges, there is a case to be argued for whether that was actually 
a weakness or a strength of the study. I think that that is a topic we could come 
back to. We didn’t have any specific hypotheses. There may have been lots of 
individual hypotheses that would have been seen as answerable by the study, but 
there were no specific driving hypotheses in terms of child development, which 
became a key issue on which a funding bid could be put forward at an early stage.
Peckham: That is a comment that would apply even to the newly funded 
cohort.41 I don’t think you can say that it was without hypothesis, because Jean 
has already said it was based on the belief that intra-uterine life and environment 
had an important impact on outcome. In a sense that is a hypothesis. As there 
is not a single question, you have to keep the study quite broad. I would 
39 See Appendix 1.
40 Dr Pollock wrote: ‘The previous national birth cohort studies were planned to be single sweep cross-
sectional studies. It might have been that researchers foresaw the opportunity for further longitudinal 
studies but they were not planned as such. When funding was later obtained for follow-ups, conducted 
usually several years later and which turned them into longitudinal studies, the sweeps probed past events 
some time retrospectively (as opposed to collecting information shortly after the events occurred as in 
ALSPAC). So, for example, data on infant feeding in the weeks and months after birth in the British Births 
Cohort 1970 study were not collected from the mother until the index child was 5 years old. The degree 
to which data are retrospectively collected is minimized, and hence data quality higher, when longitudinal 
studies are planned to be so.’ E-mail to Ms Caroline Overy, 7 December 2011. 
41 The 2012 Birth Cohort Study, funded by the Department of Business Innovation and Skills (BIS), the 
Economic and Social Research Council (ESRC) and the Medical Research Council (MRC), will be the 
largest UK-wide study of babies and young children, and will follow 90 000 children and their families 
from pregnancy through to the early years; see www.esrc.ac.uk/funding-and-guidance/tools-and-resources/
research-resources/surveys/bcf.aspx (visited 30 November 2011).
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have thought that this applied to all the birth cohorts, and I know it’s often a 
controversial issue. Going back to the discussion about funding, although in 
the minds of those who created the 1958 birth cohort study, and other similar 
studies, the overall concept was longitudinal and long term, nobody is likely to 
give you money for something that is very protracted. Even for the most recent 
new cohort currently being planned, funding is only for the first two years. Of 
course, the expectation is that it will go on for much longer. I think it’s very 
hard to build long-term funding into these studies. I remember discussions 
about the 1958 cohort when we were trying to raise funds for the follow-ups. 
In meetings in the Department of Health we had to look at each question to 
determine whether it was relevant to the longitudinal nature of the study rather 
than information which could have been gathered in a ‘single sweep’. There was 
a great deal of discussion to ensure that the cross-sectional data not essential to 
the study was excluded. I think that such discussions are extremely important 
to keep the studies tight. This brings us onto the funding. Jean, you’ve gone a 
long way without any funding. Can you tell me, what next?
golding: We got $5000 for piloting.42 [Laughter] 
Peckham: But at least you’d got your salary to be able to bring everyone on 
board.43 How did you get the first funding for the study?
golding: Well, the ideal which we tried to work towards was to get a consortium 
of funders to all put in a certain amount of funding to get the thing going. 
Peckham: What sort of funders?
golding: Government departments, research councils, particularly the MRC, 
and charities, Asthma UK, or whatever it was called then;44 Action Research;45 a 
huge number of different charities that were interested. The first thing we did to 
42 See page 6. 
43 See page 10 and note 25
44 Asthma Research Council (ARC) was founded in 1927 to conduct research into the ‘cause and cure of 
asthma from a firm scientific foundation.’ In 1989 this merged with the fundraising ‘Friends of the ARC’ 
to form the National Asthma Campaign; this became Asthma UK in 2004; www.asthma.org.uk/index.html 
(visited 31 January 2012).
45 Action Research (Action Medical Research since 2003) was founded in 1952 as the National Fund for 
Poliomyelitis with the aim of finding a cure for polio. With the introduction of the vaccine and subsequent 
reduction in the disease, the charity changed its emphasis to include other crippling diseases. Today, its aim 
is to fund medical research ‘to help stop the suffering of babies and children caused by disease and disability’; 
www.action.org.uk/ (visited 31 January 2012).
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start with, I should say the most important thing we did, was to form a steering 
committee, which had important people like you [Catherine Peckham] on it, 
and Marcus Pembrey, Gordon Stirrat and David Baum, and Michael Rutter.46 
We (i.e. the Steering Committee) worked towards having a meeting of all this 
group of potential funders and that was held in August 1989. The MRC hosted 
it and there was a good turnout of various government departments and two 
people from the MRC, and different charities. Some of the participants are here 
today: Ian Lister Cheese was there; Alan Emond was there; also Yasmin Iles-
Caven, who was my PA at the time; Marcus Pembrey, Jon Pollock and Gordon 
Stirrat. We presented the idea of ALSPAC and what it could do for government 
departments and various people, hoping that we were going to end up with, 
you know, quantities of long-term funding. We ended up with a basic: ‘well, it’s 
a really positive idea’, but my memory of what they said was that it couldn’t be 
done in that way, it had to be done with project grants. Somehow the project 
grants would be focused on specific questions and we were expected to be able 
to juggle the money so it would pay for the long-term project.
Peckham: So then you had to develop your hypotheses? [Laughter] 
golding: And how… yes. And there were various people at that meeting, who 
did have their own hypotheses that they wanted us to look at. Those from the 
Department of the Environment were the strongest ones. They’d always wanted 
to be able to access homes so they could measure air pollutants indoors and they 
hadn’t got a mechanism for doing so; and we could be the mechanism, which 
fitted in with our study of the environment and how we could do it. So, that 
was fine. We won grants here and there, but didn’t have quite enough to feel 
comfortable about starting, when I got this phone call from the Department of 
the Environment saying: ‘Why haven’t you started yet? We’ve started employing 
the people who are going to do the measurements.’ [Laughter] We were 
squeezed, so we had to start, because we’d got their money. I mean, maybe we 
could have said ‘no’, but anyway we were kick-started.
Peckham: So how did you start without any money?
golding: Well, we had some money. We had enough to keep us going until 
December 1991, which I remember well. I think most of us remember it well, 
particularly the people who were employed because that’s the point at which we 
46 Professor Sir Michael Rutter (b. 1933) is professor of developmental psychopathology at the Institute of 
Psychiatry, King’s College, London. He set up the MRC Child Psychiatry Research Unit in 1984 and the 
Social, Genetic and Developmental Psychiatry Unit at the Institute of Psychiatry in 1994.
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were definitely in the red as far as the university was concerned. And it was, you 
know, a big drop. The Steering Committee had seen it coming, and we’d been 
talking about it month after month, and writing grants galore, some of which 
we won, but it was never quite enough. That was the point at which the first 
furore happened at the Department of Child Health in Bristol, which Alan, I 
think, remembers well. Do you want to speak about that, because I wasn’t quite 
aware of what was going on?
emond: Most of the paediatricians knew that ALSPAC was being run on a 
wing and a prayer, and there was a bit of disquiet, but I think Jean had an 
aura about her that people believed that she would come through. And I think 
Jean’s greatest characteristic is her dogged optimism that things will come right. 
That inspired people like me to follow, but some of her senior colleagues were 
less sanguine about it. A note came down from higher up in the university 
that ALSPAC was in the red, and shortly after that came an open threat from 
finance that they were going to freeze all the senior academics’ discretionary 
funds to pay for the ALSPAC debt.47 I’ll never forget the reaction of my seniors 
– it was quite an eye-opener for me as a young academic about the way that 
the seniors behaved, because people just came out of the woodwork – I won’t 
mention names, but some of my senior colleagues appeared out of nowhere, 
livid that the pot of discretionary money that they’d been building up over the 
years could just go to pay for Jean Golding’s irresponsible debt. [Laughter] This 
was a major ruction that actually took some time to heal between the different 
academic paediatricians, and I’ll never forget it. We were saved because of Sir 
John Kingman, the vice-chancellor at the time, who is a statistician and really 
understood the value of longitudinal studies.48 I think Jean had lunch with him 
on a regular basis.
golding: No, I didn’t.
emond: Well, that was my fantasy anyway! [Laughter] That you somehow got 
Sir John on side and that saved our bacon. But the project very nearly went 
down the tubes.
47 See pages 22–3. 
48 Sir John Kingman was vice-chancellor of Bristol University from 1985 to 2001 and was president of the 
Royal Statistical Society from 1987 to 1989. 
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golding: I think it was getting Brian onside particularly. 
Peckham: The university role and support was clearly important. Certainly the 
steering group was very aware of that. Brian, would you like to say something 
about that?
Professor Brian Pickering: My memory is very, very hazy of those times. In 
1992, I became the deputy vice-chancellor of the University of Bristol. One of 
my jobs was to have oversight of the allocation of the university resources. So 
in fact it was me that Jean naturally tried to persuade, and we had a number of 
conversations at the time. There was, of course, a great feeling in the university 
that while university funds should be used to provide, as it was called then, 
the Well-Found Laboratory, and then also to pump prime. If a project, in its 
broadest sense, was to be viable, then outside funds had to be found.49 What 
we were doing at that time, from 1992 on, was actually trying to keep the wolf 
not just from the door, but from actually beginning to bite in the sitting room! 
As Alan said, clearly there was support from my boss, the vice-chancellor, who 
appreciated the importance of longitudinal studies; and in many respects, was 
in favour of long-term funding rather than of individual project grants. 
While there was general support for the ALSPAC activity by funders, there 
was a reluctance to fund the individual project grant applications. I think it 
came back to the ‘hypothesis’ situation and ‘fishing expeditions’, which were 
comments that were heard from time to time. 
In the university, too, there was general support for ALSPAC, and we felt that 
we ought to try and make sure that it was able to survive until it got long-term 
funding from outside. Of course, university funds are finite: if one feeds Peter, 
there are lots of Pauls who have to give up some of the crumbs and their hidden 
criticism is present all the time. As the academic in charge, I was helped by the 
enormous support of the finance director, Ian Crawford, who is down as an 
‘apology’ today.50 Ian felt that ALSPAC activities could be considered as good 
49 At that time university research was funded by the ‘dual support system’, in which core support for general 
purposes was allocated by the University Grants Committee (replaced by the University Funding Council 
in 1989, and in 1992 by the Higher Education Funding Council for England) and project-specific funds 
were gained from grants awarded by research councils, charities and industry. A report by the Advisory Board 
for the research councils (ABRC) in 1987 states: ‘University money for the support of research serves two 
purposes. On the one hand it provides for a basic level of research activity for all university academic staff. On 
the other hand it provides the “well-found” laboratory in which work supported by the Research Council and 
other funding agencies can be undertaken’. ABRC (1987), quoted in Adams and Bekhradnia (2004): 19.
50 Mr Ian Crawford joined the University of Bristol in 1990 and retired as finance director in December 2008. 
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investments: Jean and her colleagues were likely to be developing techniques that 
the university could patent in time, and, in straight business terms, it was good 
to keep this project going. This was not something that was discussed openly in 
the university, but was his personal view, which of course, made my job a little 
easier when I wanted to say ‘yes’ to Jean, rather than ‘no’. However, it became 
apparent that there was no pressure on anybody else outside to fund ALSPAC 
if the University of Bristol was doing it. I do remember coming to London 
with Jean, and indeed with Ian Crawford – the Wellcome Trust facilitated and 
hosted a meeting at which there were representatives of MRC, the Department 
of Health (DoH) and such like.51 I remember taking a rather histrionic line 
that it was not for the University of Bristol to fund the future of the nation’s 
health. There were other people there but, I think largely with support from the 
Wellcome Trust, a great deal of good came out of that meeting, and there was 
then a movement into calmer, if not really calm, waters. 
It seems to me, listening to the discussion earlier on that, perhaps with hindsight, 
this was an adversity that had a sweet use, because if there had been national 
DoH funding from the beginning, then there would have been an enormous 
amount of pressure to actually widen the study nationally, which would have lost 
the compactness that Jean was talking about, from keeping it in Avon. 
stirrat: If I may just add something. Of course, for this study to succeed there 
had to be a considerable infrastructure, it could not have functioned otherwise. 
Unfortunately the project grant model, which was dogmatically pursued by 
the funders, actually caused us huge headaches, because there was an absolute 
refusal to even consider the possibility that they should actually contribute to 
the infrastructure – this wasn’t the same as co-funding. This persisted for many 
years and came very close to scuppering the whole thing on several occasions. 
It really was only by dint of the university’s generosity and the foresight of, 
for example, Brian Pickering and Ian Crawford, that it was overcome. I think 
there’s a lesson to be learned there. 
Peckham: I think that’s important because at the time there was quite a lot of 
criticism that you were driven to do the studies that got the funding, rather than 
the studies that needed to be done. That was a major criticism that came from 
outside. 
51 Mrs Yasmin Iles-Caven wrote: ‘The date of the meeting was 29 March 1999.’ E-mail to Ms Caroline 
Overy, 13 February 2012. 
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Pembrey: I want to contribute a little bit to the funding situation at that time, 
because we’ll come back to the reason why we had decided that we ought to 
have transformed cell lines made from either the cord blood or subsequent 
blood samples. On 21 August 1989, one month before that meeting, the MRC 
meeting that we’ve heard about where everybody was there,52 I went to see Joe 
Smith, the head of the Public Health Laboratory Service in Colindale.53 It was 
a sunny day like today. I remember 9 o’clock in the morning I arrived there. 
Three-quarters of an hour later, I came out having been promised £200 000 
of cell line activity under the guidance of Alan Doyle, who sadly could not be 
present today, who was then running the cell line facility at Porton Down.54 
I came out and thought: ‘Well, that’s a breeze! £200K, three-quarters of an 
hour’, you know. [Laughter] My optimism really shot right up to the top, and I 
thought: ‘Now it’s going to be easy to get stuff from the MRC and the Wellcome 
Trust, because if we’ve got all this on board…’ [Laughter] Not at all. That was 
52 See page 16. 
53 The Public Health Laboratory Service (PHLS) is now part of the Health Protection Agency (HPA); 
the HPA Colindale services include specialist and reference microbiology services and infectious disease 
surveillance; see www.hpa.org.uk/AboutTheHPA/WhoWeAre/CentreForInfections (visited 15 December 
2011). Sir Joseph Smith became director of the Public Health Laboratory Service in August 1985, having 
previously been senior lecturer in bacteriology and immunology at the London School of Hygiene and 
Tropical Medicine. He retired in 1992. 
54 Dr Alan Doyle went on to become science programme manager at the Wellcome Trust with responsibility 
for a range of major research projects, such as longitudinal cohort studies including UK Biobank and the UK 
birth cohort studies. He is currently director of the National Information Governance Board for Health and 
Social Care. Dr Doyle wrote: ‘The European Cell Bank at Porton Down had been established with initial 
Department of Trade and Industry funding in 1984 and the Epstein-Barr virus (EBV) transformed cell 
line facility commenced as a result of specific EC funding in 1986 based upon the technology I had gained 
experience of at the UK Transplant laboratories in Bristol in 1981–84. The overall remit of the Cell Bank 
was to provide services to the medical research community but this had to be done on a cost recovery basis. 
When approached by Professor Pembrey and Professor Golding, estimates of cost for generating cell lines 
from cord blood were discussed and submitted to the potential research funders and the subsidy from the 
parent organisation PHLS would have contributed significantly in reducing the overheads. Unfortunately 
at that particular period there was a significant and influential “anti-cell line lobby” amongst the scientific 
community who viewed this as an unnecessary extravagance and far too expensive to justify almost regardless 
of context. It was a decade or more later that whole genome association studies became dependent on large 
quantities of DNA only available from cell lines derived from donor lymphocytes. The Cell Bank at Porton 
continues on with this type of support work to this day. Having said that of course creating this resource at 
the outset would have been much more efficient and cost effective. It was somewhat ironic to me that the 
investment required to create the cell line resource from ALSPAC participants was approved by a scientific 
review conducted by the Wellcome Trust and MRC in 1999/2000 after I joined WT as a programme 
manager.’ E-mail to Ms Caroline Overy, 13 February 2012.
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a little blip, thinking that it was going to be straightforward. Then it was back 
into the grind. We didn’t really get any funding on DNA until 1995, and for 
cell lines until 2001.
Peckham: So, Jean, when did it become viable? Did the funding problem, at 
least, enable you to know that you could carry on for a year without being in 
the red?
golding: It certainly wasn’t viable when we carried on. I think I was producing 
business plans on a monthly basis. We were producing lists of grants that were 
submitted, with my estimation of what the odds were of getting that particular 
money, which actually, if you multiplied the odds by the amount you’d applied 
for, and added it up, it came to what we got, but it might not have been the 
grants that we thought were going to be easy. This was the sort of system that 
we had in place, and you know, meetings every month, I think, certainly with 
the finance director. But the thing to be remembered is the effect on the staff, 
because we didn’t have money: all our staff, or almost all the staff, were on 
contracts that lasted a month; they got their notice before they got their contract 
for the next month; and then, you know, you couldn’t advertise for a post with 
that sort of funding anyway. We had so much loyalty and enthusiasm. It was: 
‘Well, we’ll hear later…’ It was just amazing.
Peckham: It was extraordinary. I don’t think that would be possible now. 
golding: I think you can get the enthusiasm, and if you’ve got the staff already 
on board, I don’t see why it’s not possible. I hope you don’t have to try it. One 
of the things that we did at that point when we went into the red, was to go 
to William Waldegrave, who happened to be the MP for our area, and he was 
the Minister of Health at the time, I think, or he had been the Minister of 
Health.55 Anyway, he knew about ALSPAC, I’d seen him before and he raised 
questions with the Department of Health, who took it seriously, but decided 
not to core fund us. But, we were trying all sorts of things. One of the business 
plans that I developed was ‘worse scenario, we stop now’; or put another way, 
‘extreme scenario number 1: we stop everything now’. The downside of that 
was that not only did you never pay the debt back, but you would also have to 
pay back that money given to you that you’d already spent on collecting data. 
55 William Waldegrave was Secretary of State for Health from 1990 until 1992, and MP for Bristol West 
from 1979 until 1997. He became Baron Waldegrave of North Hill in 1999.
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That came to about minus £250 000 that you’d never pay back. The other 
extreme was to carry on working without having the full funding to do so, on 
the understanding that the money will come in. I prophesied that it would take 
five years to get in the black again.56 I was wrong. [Laughter] But it got better, 
and you know, that’s how we carried on, but it was really John Kingman, Brian 
Pickering and Ian Crawford, particularly, that kept it going. And I think one 
of the important things was a key part of a cohort study: if you stop collecting 
data as the babies were being born because you had run out of funds, and then 
caught up with them much later, you’d wasted that vital period of time, and the 
important information that should have been collected.
Mrs yasmin iles-Caven: I was Jean’s PA for a very long time and then the 
resources manager for ALSPAC, so I know a lot about the figures and the trials 
and tribulations. I can clearly remember the day in early 1990 or so, when Jean 
called all the secretaries and me into a room and said: ‘We’re going to do this big 
study where we send out lots of questionnaires, write lots of grant applications, 
and we don’t have a budget.’ At the time, I think we were all really overwhelmed 
at the thought of all the extra work and that we didn’t actually have the money 
to finance it, but little did we know. That was in the days before we had PCs, so 
we were hand-typing these grant applications. Going back to when they almost 
shut us down in 1991: we’d already had funding – about £2 million – invested 
in the development and the first 15 months of the project, and our predicted 
shortfall was about £53 000, which doesn’t sound a lot of money now, but that 
was when things were really dire and they were going to close us down after 
Christmas.57 I should say that our debt later rose to £1.5 million or so, which 
we managed to pay back over a number of years through the indirect income 
we’d won on grants being diverted to pay it off. But it was a huge risk for the 
university. For the finance director at the time, Ian Crawford, to take that kind 
of risk was amazing and showed how much he believed in the study. By about 
56 Professor Jean Golding wrote: ‘It was never in the black, but once I had left, the university wrote off the 
debt.’ E-mail to Ms Caroline Overy, 20 December 2011.
57 Mrs Yasmin Iles-Caven wrote: ‘We’d been told not to spend or commit any more monies as we were 
£53 000 over spent already. A large number of staff who worked as interviewers or ‘Focus’ clinic staff were 
hourly paid on a casual fee claims basis and their December claims would increase that overspend by at 
least £10 000. I believe our head of department and his departmental manager were considering asking 
the ‘casual’ staff not to come back after Christmas. This would have meant the closure of the Focus clinics 
and no one to mail out questionnaires or encourage participation. Disaster was averted thanks to Jean, who 
hand wrote a long letter to the vice-chancellor, which she personally delivered across the garden gate at his 
residence during the Christmas holidays.’ E-mail to Ms Caroline Overy, 19 December 2011.
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1993, we’d estimated the running costs were going to be about £1 million a 
year because we had 70 or more staff at the time, full- and part-time, and were 
sending our questionnaires to about 15 000 families. So it was a real hand-to-
mouth existence. But we managed to beg, borrow – not quite steal – a lot of 
support in kind, like the university allowing us to use premises rent-free; the 
local hospitals allowed us to use space in their freezers to store biosamples and 
placentas; and we were able to get companies like Oral B to give toothbrushes 
as thank you gifts to the ‘Children in Focus’ groups.58 Alongside ALSPAC, of 
course, we were trying to run ELSPAC at the same time. We tried obtaining 
funding from the EU on several occasions, which had pretty tight deadlines. I 
can remember travelling to Brussels by train and ferry to deliver applications on 
time. We got some money from the National Institutes of Health (NIH) to cover 
costs in places like Russia and the Ukraine. By about the early 1990s, one-third 
of our income came from government bodies and 20 per cent from charities, 
another 20 per cent from the commercial sector, and the rest from the USA 
(NIH and the March of Dimes).59 But we did spend most of our time writing 
grant applications and fundraising letters, and we didn’t do too badly, really, I 
think. I have got quite a lot of numbers, as I’ve been archiving all the old grants 
and failed submissions, and of those grants awarded between 1989 and 2005, 
approximately, we won 176 grants and more than 258 applications failed.60
Peckham: That’s quite a high hit rate. 
iles-Caven: Yes, not bad.
Peckham: We ought to move on now to recruitment. It will be very interesting 
to know how you involved the local community; how you recruited the families. 
Who would like to talk about that?
58 Ten ‘Children in Focus’ clinics were held at various time intervals between the ages of 4 and 61 months, 
using a 10 per cent sample of the cohort selected at random from the last six months of ALSPAC births. 
Further annual Focus Clinics were held from ages 7–17 years which were open to all study children. For a 
list of funding contributions towards the ‘Children in Focus’ study by 1997, see Appendix 3.
59 The March of Dimes Foundation was set up in 1938 in the United States by President F D Roosevelt as the 
National Foundation for Infantile Paralysis (NFIP) to combat polio. In 1958, following the introduction of 
the Salk vaccine and the decline of the disease, the Foundation’s mission changed to focus on the prevention 
of birth defects, infant mortality and premature birth, and now has the broader goal of improving the health 
of all pregnant women and babies; see www.marchofdimes.com/ (visited 25 January 2012).
60 See Appendix 4 for revised figures.
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golding: I shall start by saying that one of our most important sources of 
recruitment was people knocking on the door to be members of staff. Sue 
Sadler, who is here, did that; and that was very valuable, because they already 
wanted to take part.
Peckham: How did they know about it?
Mrs sue sadler: I became the manager of the clinics after a couple of years 
of being with ALSPAC. I’d been a teacher and an antenatal teacher for some 
years and, between jobs and at a low ebb, a friend said: ‘Do you know about 
this study that Jean Golding’s doing?’ And she talked about it. ‘Why don’t you 
contact her?’ I thought: ‘What a brilliant idea.’ It sounded absolutely fabulous. 
So I did, and said, basically, not quite ‘give us a job’,61 you know, but ‘could I 
possibly come and help?’ Jean wrote back saying, ‘Well, tell me what you can do 
and some things you’ve written’, and I did and lo and behold, I got a job. I think 
it doesn’t happen anymore like that. There I was doing all sorts of jobs that were 
required before we eventually started running the clinics. 
If you want to know a bit more about recruitment from my perspective, I 
then had to take on people to examine the babies, the newborns, first of all 
to measure the newborns and later during the actual clinic. You can’t advertise 
even if you have the money, to give people jobs measuring newborns in hospital. 
It’s a very special thing to do. I was in a fortunate position because I’d been 
working with the National Childbirth Trust62 for a long time, and I knew the 
network, and knew this extremely valuable post-natal support set-up they have, 
where people who have been through the classes will then get together – sort of 
coffee mornings, what have you – but it’s a group of people whom I felt were 
the kind of people that I wanted to be talking to new mums, and handling 
these newborn babies. That’s how we got our first staff. It was word of mouth. I 
approached the organizers and asked: ‘Have you got people who want a job who 
will be suited to doing this kind of thing?’ and they came.63 When we wanted 
61 ‘Gizza job’ (Give us [me] a job) was the catchphrase of the Liverpudlian character Yossa Hughes in the 
BBC television drama Boys from the Blackstuff (1982).
62 Founded in 1956 as the National Childbirth Association, the National Childbirth Trust (NCT) obtained 
charitable status in 1961 and is now the largest UK parenting charity, offering antenatal and post-natal 
discussion classes, support groups and telephone support lines.
63 Mrs Sue Sadler wrote: ‘They did have to get through an interview first!’ Note on draft transcript, 
18 August 2011.
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staff for the new Focus Clinics64 from four months onwards, it was the same 
network of people and also people who were known by those already working 
for us. Nepotism, absolutely. But it worked because we had a very special kind 
of group of people who were very good with children and babies and mothers, 
and knew what it was like and could communicate well. 
Peckham: How did you enrol the families? And involve the community?
Mrs ruth Bowles: I’m a study mother. When I was asked to come along to 
this meeting I thought: ‘I can’t actually quite remember how I was enrolled!’ 
So I asked around and, coming back to the point of it being a local study, I 
had plenty of people I could ask because they are my contemporaries – all our 
children were involved in the study. So that’s another good reason for having 
it held locally, or in a distinct area. I was involved, and I was beginning to 
doubt my own memory, until Alan Emond spoke. In 1987 I remember taking 
part in a pilot study with my first child. I was handed a questionnaire in the 
hospital after he was born. I don’t remember much more about it apart from 
answering the questions and putting comments on saying: ‘Don’t make me read 
all the questions unless I’m going to answer them. You know, put guides to 
say, “If you’ve answered no, move on to page 22” you know, because they were 
big booklets.’ I think that must be Alan’s fault, that one. [Laughs] In terms of 
being recruited with my study child, my third child, as I say I don’t remember 
seeing any literature. My sister could remember quite clearly seeing literature 
up in the GP clinic and also the midwives mentioning it. She was attending a 
GP preconception clinic as a diabetic. But other friends also don’t remember, 
but we eventually realized that we must have been asked beforehand, and when 
I looked through some papers of mine, I have actually got a letter here which 
says: ‘Dear Mother-to-be…’ so I guess I was asked before the baby was actually 
born (see Figure 1). 
The other difficulty with that is that my third child was born at home, without 
the midwife or the GP. They came along a bit later on, so I don’t know what 
actually happened to the placenta or anything like that; whether that was kept 
or taken away. But ALSPAC found me and I answered questions from then 
on. Other friends, as I say, remember being approached perhaps by a midwife 
at some point, and so I think the midwives were probably the key people, pre-
birth, for enrolling most of the study mothers. 
64 See note 58. 
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figure 1:  Letter sent to ALsPAC parents in 1990–92 during pregnancy and  
accompanying their first questionnaire.
65
 
65 The questionnaire referred to,‘Your Environment’, may be downloaded at www.bristol.ac.uk/alspac/
documents/ques-m01-your-environment.pdf (visited 17 January 2012).
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stirrat: Yes, I can confirm that, because it certainly was mainly the midwives, 
and in my position as the professor of obstetrics and gynaecology I was able 
to talk to our midwives in Bristol Maternity Hospital, as it was then, now St 
Michael’s, and also in Southmead. We were able to make sure that there was a 
good lot of publicity for the study and a great willingness to be involved. There 
was an enthusiasm, it somehow or other just caught the spirit of the age; it got 
a lot of steam behind it. Mothers recruited mothers, etc., etc., but in fact the 
midwives were key, as usual. 
Member of the audience: As usual, yes.
Mr Mike Wall: My recollection as a study father is probably similarly vague. 
Talking with my wife before I came here, she said she remembers having blood 
being taken from her at the GP, and being asked: ‘Can we take a little bit more 
for this study?’ So, you know, blood being taken, do you want to join? Her 
reaction immediately was ‘yes’, probably without knowing very much at all, but 
very quickly we understood the benefits, or potential benefits, of this project. 
Certainly the local nature, I can reinforce that. We moved into Bristol after 
our study child was conceived and it was a talking point that helped integrate 
us into the community that we were in. In terms of recruitment to the study, 
it was straightforward. For a little bit of effort on our part, we could see the 
potential benefits, perhaps not quite as Brian Pickering said to the ‘health of the 
nation’, but we thought we could contribute in our own little way. As a study 
father I can never remember thinking: ‘Do I want to be involved with this?’ It 
was always: ‘There’s a questionnaire, yes, I’m happy to do it.’ So it was easy to 
say ‘yes’. 
Peckham: At the steering group meetings, we were always very impressed by 
the information we were shown on the feedback of information to parents 
and families, informing them about what was happening and the stage of the 
study. The focus on early feedback probably had a hugely important impact on 
recruitment. Would anyone like to say anything about how you decided on the 
materials you would use?
golding: What, for the feedback?
Peckham: Yes, the feedback, because I think this was a very important part of 
the communication.
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golding: One of the staff that came forward, a bit like Sue Sadler, was Pam 
Holmes, who was married to a TV producer who did a programme about 
ALSPAC.66 She watched it and said to him: ‘Ooh, I’d like to be part of that.’ So 
he introduced her and she had a background in publicity and public relations 
in general, so she was the person who designed our newsletters and posters and 
was particularly key in training staff on how to approach parents, because we 
had a whole network who were there to follow up if a mother hadn’t returned a 
questionnaire. If, after a reminder or two, we still hadn’t heard, they would ring 
up or call. Each of those interviewers had their own patch in the area and so got 
to know their participants very well. That was all part of what made it work.
sadler: Following on from the interviews – one of the things interviewers did 
was to go to the scan clinics to interview the mothers, and in the process of that 
visit they would identify people who were not yet part of the study. That was 
another way of catching people who had been missed at the booking clinic, 
which is where, I think, most of the midwives would introduce the study to the 
66 We have not been able to find details of this particular programme, however, ‘Children of the 90s’ was 
featured on BBC2 Close up West, 3 February 1994. This was followed by a phone-in programme on local 
BBC radio programmes.
figure 2: Card in Hindi introducing ALsPAC. 
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figure 3: expecting A Baby? Poster written in seven languages.
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000
30
figure 4: ALsPAC newsletter, Autumn 1990. 
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mothers. That was another way of doing it. We also had posters up at libraries 
and various other hospital waiting rooms, clinic waiting rooms, GP waiting 
rooms and so on, which may have attracted some people who wrote in, as many 
did from the outset. Incidentally, we also made a big effort to attract ethnic 
minority families, at least those where the mother was not English-speaking. We 
had little cards to introduce the study to the mothers printed in seven different 
Asian languages (see Figure 2).67 I remember trying to find people who would 
do that translation from a group that I had been involved with before. I don’t 
think we were hugely successful but I think it was very important that we did 
what we could. I made some visits to a local temple and a mosque and so on, 
trying to spread the word – we weren’t very successful, but we tried.
Bowles: Again, in my notes and bits and pieces – I’ve mainly kept it for my 
son, as he grew up so he could see what he’d been involved in – this [holding 
up a document] was a newsletter for professionals and is dated autumn 1990. 
In it there is a report from Dr Jean Golding, The First Two Months (see Figure 
4), and it says: ‘…we have put up posters and have made cards available in 
numerous places including chemist shops, GP surgeries and family planning 
clinics and we have had a lot of media coverage. Both cards and posters are 
available in seven ethnic minority languages [see Figures 2 and 3]. The idea is 
that the mother asks for a card which she fills in and posts to us… We hope 
that women who have not already contacted us, will be given a card by their 
community midwives. Our last chance to make contact will be to use hospital 
computer lists of names and addresses. When we get the card we send out a 
brochure which outlines in some detail exactly what is going to happen within 
the survey… Once the mother has indicated her interest in the study, she will 
be sent number of questionnaires.’ So, yes, there were lots of ways in which 
everyone learned about this study at the time to become involved in it. 
stirrat: There was, of course, one important aspect of it that we must not forget 
and that is that quite a few women were recruited early in pregnancy and not 
all those pregnancies proceeded. Of course, even when they went to term, there 
67 Mrs Sue Sadler wrote: ‘As far as I can remember, the cards were printed with text in Hindi, Urdu, Punjabi, 
Gujerati, Benghali, Chinese and Vietnamese. This was the only time we used other languages in printed 
material though we used the services of linkworkers for several years. The attempt to encourage non-English 
speaking ethnic minority women to join was not very successful. The head of the linkworkers, whom I 
knew, was herself from an immigrant family from India, said “our people are not ready to do this kind of 
altruistic work.” She also felt that they would be unlikely to be prepared to divulge personal information to 
a linkworker, even if she was from the same community.’ E-mail to Ms Caroline Overy, 8 December 2011. 
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were, unfortunately, some tragedies and some stillbirths. A huge amount of 
effort was put in to make absolutely certain that that was dealt with extremely 
sensitively, trying to balance the importance of information that might be 
obtained from such sad events – Jean might want to comment on that in a bit. 
These unfortunate women were facing this grief and tragedy, and we had to 
avoid forcing ourselves on them and adding to their grief. We had to be very 
careful to make sure that we didn’t include someone in the continuing study 
who had unfortunately lost their child. I think it is important to mention that.
golding: Yes, we did send mothers who had lost a child a special questionnaire, 
and in general, we got very favourable comments back. The sort of comments 
were: ‘Nobody’s been interested, but, you know, it has helped to write about 
what happened.’ Many of those who lost a baby at the start of the study then 
enrolled with another pregnancy later, so we hadn’t put them off.
Peckham: Very important. 
emond: One thing I would like to say, that I do regret about recruitment is that 
we didn’t enrol fathers separately and in their own right. Because, over the years, 
with family reconstitution and so on, it’s become extremely difficult to track 
men and to actually look at, not just their genetics, but also their influence on 
the family. I think it’s very important for future cohorts, and I’ve already said 
this to Carol Dezateux68 about the 2012 cohort, that men must be enrolled and 
followed up separately, and traced and tracked separately, because it’s been very 
difficult unravelling ALSPAC further down the track to work out the influence 
of the man in the family. I know men are not very good at follow-up studies, 
but they need to be enrolled in their own right.
Peckham: Do you want to add anything to that, George, in terms of your 
current work?
davey smith: I would support that comment and we are currently attempting 
formal enrolment of the fathers and partners, but obviously it probably would 
have been simpler to do it earlier, and would have been more successful. But, of 
course, given the restrictions on funding, staffing, etc., it’s difficult to do these 
things if the situation isn’t pre-planned, as it will be in the 2012 cohort.
68 Professor Carol Dezateux is director of the MRC Centre of Epidemiology for Child Health at UCL and 
leader of the scientific team responsible for the 2012 cohort; see note 41.
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golding: My memory – perhaps others can correct me – is that we deliberately 
decided not to enrol fathers and that was because we’d enrolled mothers, and we 
saw it as up to them to enrol their partner in the study if they wanted to. But 
it wasn’t up to us. Obviously the Ethics Committee considered this, Elizabeth?
Mrs elizabeth Mumford: I was secretary of the Ethics Committee at that time. 
I remember that we certainly considered the issue; it came up before the Ethics 
Committee, and we decided against it. I think we decided this because of the 
question in a lot of people’s minds about the link with the issue of paternity 
and whether mothers might be upset at the thought that the samples would 
be used for paternity tracing. I think the figures we had at the time suggested 
that something between 5 and 30 per cent of children were going to be brought 
up by men who were not their natural fathers, but not all those men knew it. 
Would opening questions about biological samples in particular raise questions 
in people’s minds and put them off the study entirely? I think, because of this, 
the Ethics Committee ruled against the idea. I don’t know whether it was your 
suggestion that we should include fathers, but certainly somebody had proposed 
it and the Ethics Committee ruled against it.
Peckham: There had been a study done on paternity, I think, about that time, 
hadn’t there, somewhere near Bristol, showing, I seem to remember, quite 
high rates of discordant partners.69 I must say, I was very impressed early on 
about how valuable the creation of the Ethics Committee was. It was more 
than an ethics committee; it was more of an advisory committee, helping to 
make decisions about what could and couldn’t be done, and how best to tackle 
problems. I thought that was very impressive and it had an important role both 
in terms of sample collections and questions asked. Now, Ian, you were involved 
in that aspect quite early on, weren’t you? 
dr ian Lister Cheese: I was a medical civil servant at the Department of 
Health at the time, and was captured by the interests of both Jean and Marcus 
separately, partly because I had policy responsibilities in child health, and also 
in genetics. At the end of the 1980s it seemed perfectly obvious that the right 
approach for the future was to study as carefully as one could the interaction of 
inborn and environmental factors in the development of children, a point made 
in the CMO’s report On the State of the Public Health for 1988.70 Yes, the Ethics 
69 For further discussion on non-paternity, see pages 36–38 and Appendix 5.
70 Sir Donald Acheson (1926–2010) was Chief Medical Officer from 1983 to 1991; see Department of 
Health (1989): 73. 
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Committee was a remarkable idea. At that time local research ethics committees 
had a very wide remit; and it became clear that they couldn’t give the deep 
and detailed and ongoing consideration to many often subtle proposals that 
the new ALSPAC Ethics Committee that eventually came into being, did. The 
committee never forgot that its first duty, its primary role, was to protect the 
participants of research. But it wasn’t its only role and that is the point that 
Catherine has just made. It wasn’t just an ethics committee, incidentally, it was 
an ethics and legal committee, and that too was important. Indeed, it reached 
further. It served as an ethics and legal and scientific appraisal committee, and 
was actually concerned to ensure that what was done was good science, but 
it also recognized that there was a tension between what might be the best 
science – in other words, what might be the fullest information that could be 
obtained, and the possible shortcomings and disadvantages of actually seeking 
that information. Some information might be potentially upsetting to parents; 
for example, where it touched on sexual health, sexual experience, questions of 
paternity, evidence of possible abuse and so on. There was a great deal of debate 
about the ways in which the study could be safeguarded and the willingness 
and keenness of participants maintained, not just at the outset, that was fairly 
easily done – you’ve seen the enthusiasm of parents from the beginning – but 
ongoing, year after year. Maintaining the reputation of ALSPAC was high 
among the concerns of the Ethics Committee. It had to preserve the reputation 
of the study. Yes, it did indeed do, and continues to do, all of these things.
stirrat: Obviously there’s a section on ethics later in the afternoon, but you 
want us to continue thinking of the Ethics and Law Committee, because I 
think this was one of David Baum’s great contributions – just one, because 
he made quite a few. It was established very early and it was the Ethics and 
Law Committee, not just Ethics. Elizabeth is a lawyer, and it was chaired by a 
professor of law, Michael Furmston, who made a great contribution over the 
years.71 That was extremely important because there were legal issues, opinions 
on which we didn’t have to pay for. But that’s a secondary matter – as a Scot I 
would remember that, but that’s not the important thing. [Laughter] Of course 
we had epidemiologists, clinicians; we ultimately had an ethicist after Alastair 
71 Michael Furmston was appointed professor of law at the University of Bristol in 1978. He retired in 1998 
and is currently emeritus professor and senior research fellow; since 2007 he has been professor of law at 
Singapore Management University.
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Campbell was appointed to the chair of ethics in medicine in 1996.72  Initially I 
pretended to be the ethicist on the committee. The committee was innovative 
in a variety of ways, one of which was that we had study mothers, including 
Ruth, as full members of the committee. That was extremely helpful. We also 
had a teacher. Ultimately, as the years progressed, we had fathers and young 
people, the progeny of ALSPAC, the ‘Children of the 90s’ themselves, now 
represented as full members. That was so, so important. 
Among the rules that were set down, we had to get the balance right of being 
sufficiently prescriptive and proscriptive to protect the participants, as Ian 
has said, without producing such inflexible rules and regulations that further 
development was prevented. I think that was managed wonderfully well. I think 
it’s a miracle that it was, but in fact, that’s actually what happened. Obviously, 
we had to have very high levels of confidentiality and anonymity, and there 
was a ‘golden rule’ that those who collected data should in no way be involved 
in analysing it. There were, of course, occasions when some of the biological 
samples, for example, showed some results that were way out of the normal 
range, and we felt we had to have an avenue of going back to the individual. In 
general, the information people got was about how things were going in general 
in the study, not about their individual results. But there were occasions in 
which we felt we had to go back to the individual and we had to lay down the 
best rules we could, before this had been thought of by any other organization. 
We came up with the working rule that one had to have a strong indication of a 
condition that had a serious risk of harm for which there was a known remedy. 
We were also sure at that time, and still are, that we were not going to divulge 
genetic information. We got quite a lot of stick for that. The trump card they 
tried to play was autonomy, you know: ‘it’s our information, it’s our right to 
get it’,73 but we were able to balance that, put autonomy in its proper place, 
with justice and with doing good and not doing harm. Given that the samples 
were not taken in clinical circumstances, didn’t have clinical rigour and were 
for epidemiological studies, I think that worked quite well. In fact, it worked 
72 Professor Alastair Campbell is the director of the Centre for Biomedical Ethics at the National University 
of Singapore. Prior to this, he was professor of ethics in medicine in the Medical School of the University 
of Bristol and Director of its Centre for Ethics in Medicine. He attended the Witness Seminar ‘Medical 
Ethics Education in Britain, 1963–1993’, Reynolds and Tansey (2007), www.history.qmul.ac.uk/research/
modbiomed/wellcome_witnesses/volume31/index.html (visited 31 January 2012).
73 Professor Gordon Stirrat wrote: ‘It was a few parents and also some lay members of ethics committees.’ 
E-mail to Ms Caroline Overy, 12 February 2012. 
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so well that when the Biobank was being set up,74 and Alistair Campbell, whose 
name I’ve mentioned already, was appointed to chair their Ethics Committee, 
he took the ALSPAC law and ethics rubric and criteria, and with some slight 
modification, applied them. That says a lot. Initially, of course, because the 
women and the participants were actually still ‘patients’, we had to put things to 
the local research ethics committees. That was not an entirely joyful experience: 
our relations with some of local research ethics committees (LREC) were fairly 
fraught, quite often due to a total misunderstanding of what it was that we 
were after, and that we were out of their comfort zone by a very long way. That 
created quite a lot of problems. We continued even although the participants 
were no longer ‘patients’ because at that time, interestingly enough, there was 
no research ethics committee within the university. That was established and the 
old habit of passing it onto LREC and their successors continued for a while, 
but certainly we now had this very clear relationship with the university research 
ethics committee. The Ethics and Law Committee was key to development and 
I think was a pathfinder in ethics and law for future studies. 
Peckham: I was impressed by it and I think it had a great influence on how the 
study was run at the beginning. That’s why I wanted to bring it up here, not just 
in the governance session later this afternoon.
stirrat: We made Jean feel fairly uncomfortable from time to time, and therefore 
I think it was a success.75 
davey smith: I was going to address your point about the non-paternity. In 
1991 there was a high profile article in the Lancet by Sally MacIntyre and 
Anne Sooman on non-paternity and the issues of prenatal genetic screening, 
which did focus attention on this and issues around the ethics of genotyping 
mothers and fathers.76 The article was very interesting because they said how 
non-paternity rates had taken on the air of urban folk tales, and they pointed 
out the uncertainty of many estimates. But even though they’d pointed out 
74 The UK Biobank, funded by the Wellcome Trust, the Medical Research Council, the Department 
of Health, the Scottish Executive and the Northwest Regional Development Agency was launched in 
Manchester in 2006 to gather biological samples and medical and lifestyle data from 500 000 people 
aged 40 to 69. It is a long-term research programme to create a national database to improve prevention, 
diagnosis and treatment of serious illness. See, for example, Elliott and Peakman (2008).
75 Professor Gordon Stirrat added an exclamation mark and noted that ‘this is meant affectionately, of 
course’. Note on draft transcript, 6 September 2011. 
76 MacIntyre and Sooman (1991). 
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that these were urban myths, that paper ended up getting quoted by some as 
the source of the famous 10 per cent figure, which it was actually a critique 
of. There were two other things: one is the importance, I think, of recruiting 
parent figures, not saying you’re recruiting them because they are the biological 
mother or biological father, but because they are parent figures, which is 
certainly something we’re attempting to do now when enrolling father figures 
in the study. But the message is quite difficult to convey, particularly because 
in a study that is set up about antenatal events, the parent figures are filling out 
questionnaires, which all appear to be about them being parents. One of the 
ALSPAC fathers was visiting me for some other reason, but then said in the lift 
that he was an ALSPAC dad and he’d dropped in to a clinic – we have drop-in 
clinics where dads are enrolled and blood samples taken at the moment – and 
I said that he was going to be invited for clinical examination. He was rather 
surprised at that because he thought we were only interested in the dads as a 
source of DNA. We try to say that the interest is in the health of the men, and 
that we are using all the information that has been collected over 20 years to 
examine this. ALSPAC is an incredibly valuable resource for looking at the dads, 
along with the mothers, in their own right, not just as the parents of the index 
child in ALSPAC. The last thing, which Marcus might talk about, is that I think 
it would also be fair to say that 20 years ago there was less interest in fathers in 
terms of having biological influences on offspring. There was a huge literature 
on maternal effects, but there was a rather limited literature on paternal effects 
in the genetic field. Interest in this has grown over the past 20 years.77
Pembrey: Yes. Obviously there were various scientific reasons why we might 
want to have samples from the fathers and this was relevant to the enrolling 
of fathers to begin with. We can cover those in the section on the genetics, 
but this question of what’s called non-paternity – unexpected paternity is the 
right phrase. It just happens that I’m responsible for the quote of 5 per cent. 
I can guarantee the source of this information, it is the Government’s figure 
in Hansard.78 I don’t think it’s been quoted since. Five per cent (and at least 5 
per cent) was what was quoted by Lord MacKay of Clashfern when the Lords 
were concerned about birth certificates and gamete donation, sperm and egg 
donation, during the lead up to the first Human Fertilisation and Embryology 
77 See, for example, Pembrey et al. (2006).
78 Human Fertilisation and Embryology Bill [H.L.] Lords Hansard; Column 1317, HL Deb, 13 February 
1990, vol 515, cols 1317–18; Lord MacKay of Clashfern was Lord Chancellor (1987–97); see Appendix 5 
for part of his speech.
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Bill in 1990. Many Lords were saying that surely the birth certificate defined 
who the biological father was, and we had to disabuse them of the fact. So 
Lord MacKay wanted a figure. It just happened, as Ian Lister Cheese will know, 
that I had been appointed in the previous year as the consultant advisor in 
genetics to the Chief Medical Officer and so it was my lot to sort this out, which 
I can assure you I did in a very scientifically rigorous way.79 There was some 
background to paternity testing at the time, but this wasn’t, of course, why we 
were interested in enrolling fathers into ALSPAC. I absolutely take the point 
that George says, that it was the father as a person that we were interested in. 
Peckham: The changing attitude to the role of fathers is interesting. Are there 
any questions that you didn’t ask that you regretted later or wished you had? Is 
there any area that you regretted you didn’t cover, with hindsight?
golding: With hindsight, I would have loved to have sent questionnaires to the 
grandparents, because that’s the generation that is very important regarding the 
parents of our study children, and it would have been good to capture them 
before they dropped off more than they had already. With work that Marcus 
and I are doing, the intergenerational effects of traumas and such things that 
happen during one’s upbringing can be passed down the generations, and that 
would have been good to capture.80 There is a biological sample I would have 
liked to capture too, which Jon Pollock piloted, and we decided we just didn’t 
have the money for, and that was breast milk. I’m sure there are lots of other 
things, but that’s today’s thought. 
Peckham: So what were the samples you collected in pregnancy? You collected 
the placentas. 
golding: We collected several maternal bloods and urines during pregnancy, the 
placentas, the umbilical cord tissue and cord blood.
Peckham: We’ll be talking about those later. Are there any other questions or 
issues that we need to highlight in the areas that we’ve already discussed?
79 Professor Marcus Pembrey wrote: ‘In the last few decades of the twentieth century, an experienced 
practitioner in each of the main medical disciplines was appointed to advise the Chief Medical Officer on a 
relatively ad hoc basis. A consultant advisor in genetics was established in 1972 (Cedric Carter), Rodney Harris 
followed him and I was the third (1989–98)’. E-mail to Ms Caroline Overy, 1 January 2012.
80 See, for example, Pembrey et al. (2006). 
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emond: The other reflection I’d like to make is about the issue of consent, 
because when consenting for a longitudinal study you’ve really got to try to 
anticipate what the consent parameters, the ethical parameters, will be in the 
future. It’s very difficult. In retrospect, the consent we got from the mothers for 
engagement in ALSPAC was fine at the time, but it’s proved tricky further down 
the track as expectations on consent have got greater. So, for example, we’re 
re-consenting the young people for record linkage, whereas when the mothers 
were pregnant we gained opt-out consent for access to medical records. It’s not 
the same thing. That is a reflection for future cohorts, to try to think slightly 
longitudinally about consent and what it could mean in the future, not the 
standard at the moment. You can bet your bottom dollar it will change.
Peckham: In the 1958 cohort in the early phase, no consent was sought. 
Information was collected by health visitors who were already visiting the 
families. It merely formalized their activities and they felt very much part of the 
study. It becomes more difficult when the child becomes an adult and consent 
is sought from them rather than the mother.
sadler: There is something we’ve touched on, particularly talking about ethics 
and recruitment and so on, but I’d like to mention it in a different way, and that 
is the way we treated our families. I should have said something about it when 
talking about recruiting staff. I went on recruiting many people for the rest of 
my time in ALSPAC, and the thing I was always looking for first was the right 
person, one who had the warmth, the sensitivity, the interest and the ability to 
make a rapport – that was the word, you know – to make a rapport quickly with 
the families, who had the interest of the family very much at heart. That sort of 
ethos of the study which came originally from Jean, I think, and also came from 
the Ethics Committee. I want to read you a paragraph, if I may, of what I used 
to say, and which we had to bring up in our induction of staff. It wasn’t only me 
who did that, it was other team members, but it went:
We aim to collect the maximum number of repeatable data on every 
child and we aim to make every child’s and every family’s experience 
of their visit positive. When there is a potential conflict between these 
two, the child’s need comes first. So if the child has reservations that 
you cannot readily overcome, or is experiencing pain or distress, and 
wants you to stop, you do. The child is in charge. That applies even 
when the parent is telling you to go ahead, or the child not to make a 
fuss. The trick is to handle the situation so that both feel good about it. 
The danger of not doing so is obvious: we may do harm to the child, the 
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family may not come back, they may tell their friends and peers. We are 
a longitudinal study: we rely on having repeat measures over time and 
on maximizing numbers.81 
I think that, along with everything we did, that was an example of the way we 
dealt with the families and the respect and gratitude that we had, and the way 
we kept it longitudinal. It was practical as well as caring.
Peckham: That was a nice statement. 
Bowles: Respect for the participants is key in explaining why people have remained 
interested in the study. Reading back through my records as well, I remember 
taking part in different aspects of the science; so putting the test tubes outside the 
window, having to record the temperature of the room, that was actually taking 
part in science.82 I think lots of people don’t have that opportunity. For future 
studies, I think giving something for the individuals to do is also quite good in 
maintaining interest. How reliable that is is a different matter, but people were 
actually taking part in the science. A lot of people that I spoke to, the other 
mothers, at one point were quite upset to hear that the study might stop because 
of the lack of funding, whilst recognizing how valuable all the science was. 
Peckham: And how much do the children appreciate it now? That’s obviously 
very important, isn’t it?
Bowles: Throughout all the various Focus Clinics, my son was involved in a 
Focus Clinic right from the start, each time they went they were given different, 
interesting things to do. They may have been given a picture to take home with 
them of some interesting aspect of their body, you know, so a retinal image or 
something, that they would never have the opportunity to see anywhere else. 
They could have any of the bone scans that had been done, get an image of that, 
for example (see Figure 5). All of those sorts of things helped to maintain the 
interest for the children who have been involved, but also the parents as well. As 
I say, taking part in the science.
Wall: Can I just say, as a study father, I think my son always enjoyed going 
to the annual or the study days, and I certainly remember him describing it 
as a ‘fun day’, and I’d reinforce that that was really important in retaining his 
interest in the study over the longer term. 
81 Written by Mrs Sue Sadler for use by the team leaders in the training of new staff.
82 For the letter of instructions for the ALSPAC air study, see Appendix 6.
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figure 5: total body bone density scan given to a participant at the focus group 9+.
stirrat: There were also parties and that sort of thing for them, and Jean can 
comment further on that. There was good fun to be had. But when they became 
teenagers, a Teenage Advisory Panel was set up of the young people, and it was 
tremendous to be involved with them, it really was.83 They were engaged and 
interested, and asked some very difficult questions. Three of them then came 
and sat in on the Ethics and Law Committee for a while before becoming full 
members. They really asked some very, very hard questions and it was very 
83 For details of the Teenage Advisory Panel, see Appendix 7.
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important that they were not patronized.84 I think we had a little bit of difficulty 
with that to begin with and some of them were a little bit upset about that. I 
think we ultimately got that right and their inclusion was a valuable innovation. 
It was not just public relations, it was much more fundamental and important 
than that. It involved them in the study and kept them coming. Although, of 
course, young men are not so amenable to continuing in this study perhaps as 
young women and there was a bit more fall off among the former.85 So that’s 
another very positive aspect: the Teenage Advisory Panel was really very good. 
Peckham: it seems to me that a lot of what has been said is very much due to the 
fact that it is a local study, there is a total buying-in by the community. I think 
this would have been much more problematic if the cohort had been recruited 
across the whole country; based on your experience it will be very interesting to 
see how these issues are addressed in the new cohort. 
golding: I think one of the interesting things will be to see whether the 
‘Children of the 90s’, the children in ALSPAC, have had an influence on what 
people decide to do in terms of the A-levels they take; the university courses 
they do, whether it’s related to some of the things we have studied with them, 
and whether that’s different from the cohorts that went before or come after, 
which should be easy to do, actually.
davey smith: Whilst it doesn’t really relate to what Jean said, one issue is, that it’s 
been found that some people who would have been eligible to be recruited into 
‘Children in the 90s’ but for various reasons weren’t, and we are now obviously 
trying to get permission for record linkage, etc. If we do get permission it 
will actually be possible, in an almost experimental way, to see the differences 
between those who were recruited and those who weren’t. 
Peckham: I would like to start with the collection of the samples, because I 
think that this study was unique in that it did collect placenta samples. You were 
involved, weren’t you, Sue, in the collection of the cord bloods, the placenta, 
antenatal samples and blood samples?
84 Professor Gordon Stirrat wrote: ‘When you have a group of senior academics and very experienced lay 
people talking about important matters affecting the study it took some time to find the right balance 
between talking above the heads of the young people and being thought to be talking down to them.’ E-mail 
to Ms Caroline Overy, 11 December 2011.
85 Professor Gordon Stirrat wrote: ‘Between the ages of 16–18 years, the number of girls still participating 
was 57 per cent and boys 42 per cent.’ E-mail to Ms Caroline Overy, 20 December 2011.
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sadler: Yes, only in the sense that I was one of, and a very, very junior member 
of, the biological samples team.
Peckham: You will remember it well then. [Laughter] 
sadler: I was the gofer, I think. 
Peckham: You can tell the truth. [Laughter] 
sadler: I’ve had a chance to look over the minutes again, thanks to Yasmin and 
Jean, but my memory is that the two main problems were whether we got the 
samples from all the women and from all the different hospitals, and when we 
got them what on earth were we going to do with them? In the sense that there 
simply wasn’t the space to store these things. The -20˚C space for the urines and 
the -70˚C, as we then had to have for the bloods.86 The cost of providing this 
space was, of course, beyond us at the time, wasn’t it, team? One or two things 
do come back to me, and I think they are quite important: one is the way we 
had to work. I often had to go around talking to midwives in different hospitals 
and clinics, and that reminds me of just how much these midwives did for the 
study. For heaven’s sake, they had a job to do, their concern was for the mothers 
and their babies, and that’s a full-time business, but they were still willing to 
find the time to fill extra tubes and consult the mother to get her agreement, 
and talk to her about the placenta, record her details and so on and so on – 
and, to do it properly. We had problems with some areas where the midwives 
were getting it wrong, or they hadn’t got the right tubes or what have you, but 
basically they were willing to do it, the vast majority of them, and I think that’s 
extraordinary. It came from the top: the midwife managers were prepared to 
help, and obviously Gordon Stirrat had a huge influence over that. It was typical 
of the goodwill that this study attracted, and the generosity. When it came to 
spaces in freezers and so on, I remember Professor Mott87 offering part of his 
-70˚C freezer, for example. Other people offered a bit of their lab space. Things 
over and above what people needed to do. 
Peckham: The mothers were quite happy about the samples being taken? There 
was no concern there? Did they know what they were for?
86 -70˚C is the optimal temperature to store samples to avoid degradation and in terms of future stability; 
see, for example, Elliott and Peakman (2008). 
87 Martin V Mott, emeritus professor of paediatric oncology. 
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sadler: Well, I can only imagine that some of them must not have done because 
what we were getting was, if not samples from all the births, certainly the very 
large majority of them, and I suspect that some of those were not actually people 
who were enrolled. Jean will probably correct me if I’m wrong.
golding: What we did at birth was to ask the midwives at delivery to save the 
placentas, regardless of whether the mother was part of ‘Children of the 90s’ 
or not. We would sort it out later. We would only analyse their placentas or 
the cord blood if we had their written permission, but at the time we wouldn’t 
know, and you couldn’t get that sorted out in time. So that when the mothers 
enrolled in pregnancy, they had a brochure that described that we would be 
collecting placentas and cord blood, but we wouldn’t touch them until we had 
their signed permission. The signed permission would have been got during 
pregnancy wherever possible. We paid some of our staff to go into the ultrasound 
clinics that did scans at 18 weeks’ or 16 weeks’ gestation. Our staff were there to 
chat up the mothers and ask if they would consent to their biological samples 
being analysed. So, that was an important part of the antenatal process. If we 
hadn’t got permission or hadn’t had time to contact them, then we would try 
and contact them later, but I think that was more by post than anything else. 
But it was the personal discussion that was important, but midwives couldn’t 
do that at the time of delivery when all sorts of clinical things were happening. 
stirrat: Of course, there’s an area here that is not mentioned: a group of unsung 
heroes, because there was the collection of data as well, extracted from the 
case notes, with permission. This group of wonderful nurses and midwives – I 
think Sue could probably talk about them88 – did a tremendous job of trying to 
understand my handwriting, for example, and trying to collect the relevant data 
from the case notes. That was extremely important as one aspect of collection.
golding: Gordon, that’s still going on. We’re still trying to translate you. 
[Laughter] 
Peckham: That was data on the pregnancy complications?
stirrat: The data on each of the indexed pregnancies of the mothers, yes. 
88 Professor Gordon Stirrat wrote: ‘On discussion I have ascertained that Sue Sadler was not involved in the 
abstraction of obstetric data from medical records. Trudy Goodenough initially supervised the team who 
were already in place having just finished data abstraction for the Vitamin K and “Cancer in Childhood” 
study (appointed and trained by Karen Birmingham). When Karen returned from a year abroad, she took 
over the supervision of the team and continued in that role for a decade or so.’ E-mail to Ms Caroline Overy, 
20 December 2011. 
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Peckham: That’s still being analysed at the moment?
golding: No, it’s one of the things we stopped doing when we ran out of money, 
and we’ve only done it when we’ve had the money to do it, unlike everything 
else. We had thought that the computer system in each of the big maternity 
hospitals was going to give us the data that we wanted, and we did a pilot study, 
and it was basically rubbish. So we had to, and are still having to, extract the 
information from the medical records. Medical records can be six inches thick; 
it’s not a trivial exercise. 
Peckham: No, I know it’s not.
golding: So we have had trained staff that Karen Birmingham supervised for quite 
a long time, and extracted data on 8 000 of our 13 000, nearly 14 000, deliveries. 
There are 5 500 left to do, and they will be destroyed in 2015, so we’re trying hard 
to get the money to do that. That’s rather critical to looking at factors operating 
during pregnancy that are clinically relevant; the sort of medication used, etc.
Peckham: What about the documentation that went with the placentas?
golding: There wasn’t any documentation. [Laughs] It depended on which 
hospital; the placentas were put into formalin with an identifying label, to be 
sorted out. The cord blood similarly; there was a sample that was kept in a 
fridge which was for clinical purposes, and retrieved when it was no longer 
needed, and then an extra sample taken if we were lucky. 
dr sue ring: I’m now head of the ALSPAC laboratories, and I want to say that 
I wasn’t around when all the samples were collected, but I think that there was a 
lot of work going on behind the scenes in the lab that people aren’t mentioning. 
The documentation we have in the lab is very good. We have dates that samples 
were collected, dates that they were aliquoted and frozen down; and it wasn’t 
just a case of a sample being taken and put in a fridge. 
Peckham: Alan, you were telling me a story earlier about the placentas. I wonder 
if you could tell us all?
emond: It was common practice, but not widely known, that maternity hospitals 
used to sell placentas for cosmetics.89 It was traditionally viewed by the midwives 
as a bit of a perk, and the money that was gained, I think in most hospitals, 
89 Professor Emond wrote: ‘The placenta is a source of oestrogen, which is used in anti-ageing skin creams; 
there are occasional newspaper articles about this practice, see, for example, Sawyer (2008).’ E-mail to 
Ms Caroline Overy, 2 February 2012.
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went into what was effectively a slush fund for midwives to use. It was only 
a small amount of money per placenta and I suspect the cosmetic companies 
made huge profits out of it. The important thing was that most women who 
delivered didn’t know that that was going to happen, and the hospitals were, 
in my view, unethical in not telling them. So when ALSPAC came along and 
wanted to take the placentas away, this was a potential barrier to the midwives’ 
participation, so Jean found a solution, as you might imagine. [Laughter] 
golding: Extra costs.
emond: I’m not sure how it was funded, but we managed to pay 50p per 
placenta. 
Peckham: So what happened to the placentas that they kept, that you didn’t 
want?
golding: We didn’t sort them; we kept all the placentas.
Peckham: Even though they weren’t study placentas?
golding: We didn’t know that they weren’t study placentas for a while.
Peckham: So you had to store all the placentas?
golding: Most of them were. I mean, we were enrolling 80+ per cent of all 
pregnancies.
Pembrey: Can I just come back to the question that Sue Ring had asked: what 
actually happened with these samples? Obviously leading up to the deliveries there 
was a lot of discussion about what samples needed to be collected, but they went 
into the NHS system. Charles Pennock was the head of biochemistry or chemical 
pathology,90 and they got stored there and properly labelled in various ways. For 
example, I can talk about the sample that was there for DNA extraction: there was 
no way the Law and Ethics Committee would allow us to extract the DNA until 
the consents from the mothers for the analysis had been computer linked with 
the samples. So there was quite a lag, a year or two or more probably, between the 
samples being carefully collected and the consents being linked to them and their 
having their final resting place, as it were, ready for use. One thing I would like to 
know beyond just the blood samples and placenta; what about the tooth fairy and 
things like that? I’ve always wondered who organized that?
90 Dr Charles Pennock worked for the Bristol and Weston Health Authority, becoming a consultant in 
paediatric chemical pathology; in 1972 he was appointed senior lecturer in child health at the University 
of Bristol.
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sadler: We sent letters out to parents about the tooth fairy, and then we sent 
out packages for them to send the teeth in to us. Kaija Turvey was responsible, 
I think, for logging the teeth in when they arrived.
golding: We then sent back a badge at great expense [Laughter] to thank the 
child. I heard from another cohort study that they’d found the tooth fairy a 
great problem politically; I think it was the Christchurch New Zealand study 
that found that in trying to be the tooth fairy by giving money for the tooth, 
they were giving more money than many of the normal mothers in their study 
would have actually paid – this was seen as a disaster from their point of view.91 
Conversely, the alternative, if you paid less, would have been a disaster. So we 
decided on financial grounds too, that we certainly wouldn’t pay, we would give 
a badge.
sadler: We did have the newsletter didn’t we, to help? We had articles in there 
and pictures of the tooth fairy, our tooth fairy, which was Kaija (see Figure 6), 
to encourage the children to understand what it was being done for as well.92
Miss karen Birmingham: I was also extremely junior at the start of ALSPAC, 
but one thing I was asked to do, as I had a nursing background, was to pilot 
some of the biological samples.93 One which I have just remembered was that 
I had to go to get antenatal urine from two GP practices. Two GP practices in 
rather deprived areas of Bristol were chosen, and we arranged to go along. I 
don’t know, I have asked Elizabeth and she says she doesn’t remember this going 
through the Ethics Committee, but, I sat in the treatment room sluice and the 
midwives would bring me these samples of urine, and I would put a number on 
them and take them back to ALSPAC. I wasn’t quite sure what was happening 
to them but I gather they were analysed for, among other things, illicit drugs, 
and I think that cannabis came out quite high, higher than expected. The next 
91 See Fergusson et al. (1989). The Christchurch Health and Development Study tooth fairy inflated 
the going-rate for teeth by 150 per cent from 20 cents to 50 cents; see David Fergusson’s speech: The 
Christchurch Health and Development Study, at /www.parliament.nsw.gov.au/prod/parlment/committee.
nsf/0/c33c46f2a40e4e0cca256c2a0006a7fe/$FILE/The%20Development%20of%20Wellbeing%20
in%20Children%20Part%202%20Fergusson.pdf, 19–20 (visited 11 January 2012).
92 Funded by the National Asthma Campaign, studies carried out on children’s two top front teeth, which 
begin to develop before birth, showed that they contained a detailed record of pre-birth exposure to trace 
elements and minerals; see www.bristol.ac.uk/alspac/documents/tooth-fairy.pdf (visited 4 October 2011).
93 Miss Karen Birmingham wrote: ‘Only antenatal urine samples were collected in this particular example. 
I also piloted the collection of cord blood for cell line transformation and placentas but this is not relevant 
in this context.’ E-mail to Ms Caroline Overy, 9 December 2011. 
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thing I knew, as a very junior member of staff, was a consultant obstetrician 
ringing me up and saying he wanted the names of all these mothers. I said, 
‘Well, they were collected anonymously so I’m afraid I can’t give them.’ ‘Don’t 
give me that! I shall go to Jean Golding and find them.’ A lot of pressure was 
put on me. They were anonymous, thank goodness, but I did think that was, 
well, I was very glad they were anonymous, because he was quite threatening in 
order to get it, because he was responsible for these people’s care; they were his 
patients and he needed to know who they were. 
Peckham: Did the mothers know what the urines were being tested for? Now 
you would have to get consent to do this.
Birmingham: Absolutely. 
golding: This wasn’t an ALSPAC sample. This was a pilot to see what the 
problems were likely to be. It was a pilot.
figure 6: kaija turvey, the ALsPAC tooth fairy,  ALsPAC newsletter 26 2003.
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Peckham: It was still without consent?
golding: Yes.
Peckham: You couldn’t do that now without consent. We had problems with 
the collection of oral fluids in the Millennium cohort.94 You might not know 
who they are, but you still need consent to collect the samples. No doubt that 
would have gone through your Ethics Committee?
Birmingham: I don’t think it did go through the Ethics Committee. I think it 
happened before the Ethics Committee was set up. It was definitely a pilot to 
see how easy or difficult it was to get hold of urine from the GP practices. One 
other thing, because I was in charge, for quite a long time, of supervising the 
midwives collecting data from medical records, and talking about handwriting: 
there was one midwife whose handwriting we all recognized; she was very well 
known. The blood pressures antenatally for every woman she ever took blood 
pressure from was 120/70. [Laughter] 
dr richard Jones: I worked in the labs at ALSPAC for a while. Before we 
lose sight of the neonatal cord samples, I want to underline what a brilliant 
opportunity birth is for sample collection. You never get as much blood from 
the infant again for many years. My second observation is that the quality of 
those samples, certainly in ALSPAC, was very good, whereas a lot of earlier 
collections from the mother were compromised from the difficult situations in 
which they were collected by ALSPAC. 
Peckham: A lot of studies have had difficulties in collecting cord samples 
because you cannot predict when women will deliver and there are often locum 
midwives on duty and you miss your samples.95
94 Professor Catherine Peckham wrote: ‘Consent was obtained from the parent for the collection of oral 
fluids in the Millennium cohort. The recording of this consent is essential as problems arose when samples 
were sent to the lab and tested but subsequent data linkage did not record consent in all cases.’ E-mail to 
Ms Caroline Overy, 6 February 2012. For the collection of oral fluid samples, see Bartington et al. (2009). 
95 Professor Catherine Peckham wrote: ‘… there are often locum midwives on duty who have not been 
trained to take the samples correctly or are not aware of the protocol and consent. We had experience 
of this in a large prospective study of CMV infection in pregnancy and had to abandon this.’ E-mail 
to Ms Caroline Overy, 6 February 2012. The NHS Cord Blood Bank for voluntary donations of cord 
blood after birth opened in London in November 2011, www.nhsbt.nhs.uk/cordblood/index.asp (visited 
11 January 2012). See also Ong et al. (1999).
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Jones: ALSPAC did it, and birth is an absolute golden opportunity. It’s one of 
the major arguments, from a biological point of view, for having recruitment 
before birth. Clearly you won’t get anything decent retrospectively from that 
time point. If you wanted to establish a DNA collection, with the benefit of 
hindsight again, cord bloods would have been a perfect opportunity both in 
terms of the quality of the sample and the coverage that is potentially there. 
Coverage is far, far more difficult in later stages.96 
stirrat: You asked Jean about missed opportunities and in fact Marcus has 
referred to a visit to Porton Down. A group of us went and that was the golden 
opportunity for establishing a DNA collection from cord bloods, because 
that’s what was planned. If you’re looking at one of the things that was a major 
disappointment and in fact, ultimately, has probably cost a great deal more and 
produced a great deal less information on DNA, it was the turning down of the 
request to actually immortalize these cell lines from umbilical cords.97 That was 
a missed opportunity which can never be repeated. 
Peckham: That’s important to document.
golding: Charles Pennock98 didn’t actually believe that there was much point in 
collecting these biological samples. He was facilitating it, but thought nobody 
was ever going to want to do anything with them; it was a waste of time, a waste 
of money, and at the end of a meeting he used to say: ‘I’m ALSPACed’, which 
meant, you know, just too much. However, the fact that he kept doing it and 
the data is in such a good state is, I think, amazing. 
ring: I want to pick up on Gordon’s comment there that it was a missed 
opportunity with the cord bloods and not getting cell lines. In retrospect now, 
I don’t think that’s true. Some of the epigenetics projects that we’re currently 
working on are dependent on using DNA extracted from the white cells that 
96 See, for example, Moise (2005). 
97 Professor Gordon Stirrat wrote: ‘In fact Porton Down did not turn down the request; indeed they were 
eager to be involved in the creation of cell lines. Unfortunately (and in my opinion short-sightedly) none of 
the funding bodies was prepared to fund this initiative.’ E-mail to Ms Caroline Overy, 20 December 2011.
98 See note 90.
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were not transformed.99 Therefore the samples that were collected are very, very 
useful for epigenetic projects and if we hadn’t had those samples, that would 
have been a missed opportunity now.
Peckham: So there has been a gain and a loss.
Jones: Did you mean, Sue, the ability to compare the DNA collected at birth 
with DNA collected later?
ring: Yes, exactly, which is what we are now doing.
Peckham: Can you distinguish easily between maternal DNA and child DNA? 
I mean, when you have cord samples? Is that not sometimes a problem?
ring: I don’t think it really is a problem. We did some studies very early on 
where we were looking at the samples from boys to see if any had evidence of 
two X chromosomes, and it was a small number, less than 1per cent.
golding: One thing that we haven’t covered is collecting the samples from the 
children themselves, because that was very important. And we had this 10 per 
cent sample of Children in Focus that we took heel prick samples from. Now 
heel prick samples are actually very painful …100
Peckham: It depends on the age, doesn’t it?
golding: I think even if you’re a four-month-old it is painful. When we started 
using venepuncture, we used an anaesthetic cream and that worked much better, 
and was much less of a hassle and less painful for the child, and the parent.101 
99 Epigenetics is the study of heritable changes in gene expression that do not involve changes in DNA 
sequence; see notes 114 and 138. Dr Sue Ring wrote: ‘We currently have funding (ARIES project funded by 
the Biotechnology and Biological Sciences Research Council (BBSRC)) to obtain epigenetic data (Illumina 
HumanMethylation450 BeadChip) on serial samples for 1000 mother-child pairs using DNA extracted 
from blood taken from the children at birth (cord blood), 7 years and 15–17 years and from their mothers 
during pregnancy and 15 to 17 years later. The first paper related to this work is Relton et al. (2012).’ E-mail 
to Ms Caroline Overy, 30 January 2012.
100 On heel pricks, see, for example, Owens and Todt (1984); Slater et al. (2006). For an ALSPAC ‘Children 
in Focus’ study using the heel prick, see Emond et al. (1996). 
101 For heel prick vs venepuncture, see, for example, Shah et al. (1997); Shah and Ohlsson (2007).
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So blood samples were possible, the Ethics Committee approved of them, and 
we’ve collected other biological samples from the children as well. Some of the 
offspring give blood every time they come nowadays.102
Peckham: That’s very interesting. Marcus, you were on the Ethics Committee 
of the British Paediatric Association (BPA), as it was then,103 when it looked at 
ethics in research in children and concluded that taking a blood sample from a 
normal child was invasive and not ethical.104 
Pembrey: Yes. It was indeed.
Peckham: I remember the debates that went on around this issue.
Pembrey: It was indeed and I absolutely want to reiterate my admiration for the 
system they [ALSPAC] had for taking venepunctures from children. This was 
probably the first time EMLA cream105 was used in epidemiological scale studies. 
Of course, in hospital EMLA cream, the anaesthetic cream, got a slightly bad 
reputation. The child usually had it put on for too short a time, and it was 
clearly linked psychologically with having the needle, whereas the way they 
sorted it out in the clinic for ALSPAC was absolutely admirable, you know. The 
magic cream would be put on and then they would be doing all sorts of other 
things and exactly three quarters of an hour later, or whatever it was, they then 
came back.106 I understand that more often than not the toddlers cried because 
the video of Postman Pat had been turned off than during the venepuncture, so 
it was brilliant.
102 Blood, hair and urine were collected at the 15+ and 17+ clinics. Dr Larisa Duffy, head of fieldwork 
for ALSPAC, wrote: ‘There is not currently a clinic for study children but there is a plan to have a sweep 
in 2014/15. Also there is a number of sub-studies taking place currently but they involve a small subset 
of the cohort (either by genotype or phenotype) and often do not include the blood sample.’ E-mail to 
Ms Caroline Overy, 8 March 2012.
103 Now the Royal College of Paediatrics and Child Health; it received Royal College status in 1996.
104 Professor Marcus Pembrey supplied the following reference: ‘LOW risk procedures that cause brief 
pain or tenderness, and small bruises or scars. Many children fear needles and for them LOW rather than 
MINIMAL risks are often incurred by injections or venepuncture… It would be unethical to submit child 
subjects to more than MINIMAL risk when the procedure offers no benefit to them, or only a slight or very 
uncertain one.’ British Paediatric Association (1992): 4.’ E-mail to Ms Caroline Overy, 1 January 2012.
105 EMLA®, a registered trademark of APP Pharmaceuticals, is a local anaesthetic (an abbreviation for 
Eutectic Mixture of Local Anesthetics), containing 2.5% lidocaine (lignocaine) and 2.5% prilocaine.
106 On the use of EMLA cream, see, for example, Lander et al. (1996); Rogers and Ostrow (2004).
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Peckham: What age were these children?
sadler: We started at age two, I think. It was either two or two-and-a-half, wasn’t 
it, Jean? Two-and-a-half, we started – I’ve got a picture somewhere here (see Figure 
8) – 31 months, yes. Two and a half. Exactly as Marcus said, the venepunctures 
worked brilliantly. We took a lot of trouble getting it right, though. We had a 
play leader from the hospital to talk about playing with the children, distracting 
them during the procedure. We had these wonderful videos: Postman Pat was the 
first one we used, because they got older as we went on. We also took a lot of 
trouble over the technique. We ended up using Sarstedt Monovettes,107 which I 
don’t think were much used in the hospitals, but with butterflies.108 We had the 
rep down and one of his assistants thoroughly trained the staff in using them 
because I don’t think many of them had actually used them before. We very, very 
rarely used a syringe. It was exceptional if one of the people used a syringe. The 
other thing is, we chose our blood takers with enormous care. For many, many 
years these were very experienced paediatric phlebotomists; we only used them 
for most of the time I was there. Towards the end of my time, which was in 2008, 
we had spent a couple of years using them to train up one or two of the staff that 
were suitable, were keen and interested to do it, and several of them became also 
extremely good phlebotomists. Phlebotomy in children is a real art: you really 
need people who are expert at it, and we had a team who could get blood out of 
anything, I swear. They were absolutely brilliant and it was so rare for a child to 
be in the least bit bothered. 
107 The Sarstedt S-Monovette® is a closed blood collection system that collects blood using either the 
aspiration or vacuum principle of collection.
108 Mrs Sue Sadler wrote: ‘… phlebotomists at the time …were used to using syringes. Ours had to be 
trained to use the Monovettes, but once practised with them and the butterfly needles, they found them 
much simpler to use on small children. We used EMLA cream too, put on an hour in advance.’ E-mail to 
Ms Caroline Overy, 8 December 2011.
figure 7: information on blood sampling from the focus@7 leaflet. 
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figure 8: taking blood at the 2½ year clinic.
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It’s very sad that subsequently that team were not taken on again when things 
changed at the clinics. It’s a great grief to me that they were lost as a whole, as a 
group. Because it was felt important that people were able to do blood-taking as 
well as this, that and the other. But these highly qualified people were absolutely 
brilliant and trained some other people to be as good. 
Peckham: Was this taken up in the Ethics Committee, because this would have 
been quite interesting?
Mumford: Yes, the Ethics Committee was acutely aware of what was going on 
at the British Paediatric Association.109 Various other regulatory bodies had also 
issued guidance.110 There was quite a controversy at the time.111 There was a lot 
of discussion about terminology in an attempt to set the appropriate standard: 
which words to use. People talked of ‘minimal risk’ versus ‘negligible risk’. What 
we did was to go along and watch. We were invited and so we went and observed 
blood being taken with real interest. I was certainly one of those who was not 
convinced that having blood taken was not going to be distressing for the child. 
That was the benchmark that we had decided to use: would it cause distress for 
the children? When we left, I was convinced, as was, I think, everybody else on 
the committee: we saw the whole procedure and we felt that it was genuinely 
not causing distress. The children appeared relaxed; they appeared happy as they 
sat watching the video and that convinced us that we could give ethical approval 
for the venepuncture. The other thing that we did, when the children were 
aged four or five, was to start allowing them to make the decision themselves 
whether they were going to give blood. This was no longer purely a parental 
decision. At that age, children are clearly not old enough to give consent in the 
legal sense, but we allowed them to say ‘yes’ or ‘no’, in a meaningful way, that 
109 British Paediatric Association (1992); see note 103.
110 For example, Royal College of Physicians (1990); Medical Research Council (1991).
111 Mrs Elizabeth Mumford wrote: ‘It wasn’t really a controversy – just discussion about the meanings of 
different terms. The US National Commission for the Protection of Human Subjects of Biomedical and 
Behavioural Research (Belmont Report, 1978) came up with the idea of “minimal risk”; British Paediatric 
Association (1980) used this interchangeably with “negligible”. Then they both tried to define this (e.g. less 
than that occurring in everyday life). There was subsequent discussion about what these terms really meant 
and how much risk children faced in everyday life (quite a bit) and whether this was really acceptable, etc. 
The terms and what they include have changed over time too. For example, the 2004 MRC Ethics Guide 
(Medical Research Involving Children) now describes venepuncture as of “low” rather than “minimal” risk.’ 
E-mails to Ms Caroline Overy, 11 January and 18 February 2012.
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figure 9: Chart given to midwives for the collection of samples in pregnancy and at birth.
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we took seriously from quite an early age. So that’s another way in which we 
resolved the problem.
Peckham: Very interesting. Lessons to be learned for now, I think.
sadler: If anyone is interested in seeing pictures of a child going through this, I 
have a set in these documents, so I’ll leave those around at the end (see Figure 8). 
I also have a copy of the chart that we gave to all the midwives to show them 
what needed to be done at different stages (see Figure 9). That’s quite impressive 
when you think of how much they had to do, so I’ll leave those around at 
the end. 
Peckham: There still is a general view that you can’t take blood from children, 
and probably you’ve got to put this into a context where it can be done easily 
and safely. Marcus, would you like to tell us when the genetic issues were first 
discussed? 
Pembrey: Yes. I think it’s important to go back a bit because the genetics 
community, before Jean and I met in Athens,112 had made quite a lot of progress 
in the 1980s. Some Mendelian disorders had been mapped, there was prenatal 
diagnosis, carrier testing by linkage, those types of things and, by the end of 
the 1980s, we started seeing these unusual inheritance patterns. I happen to 
be involved in this genomic imprinting research,113 where a gene is only active 
when transmitted by either the mother or the father. That is, normal DNA was 
silenced in some way.114 By that time people were beginning to think that the 
real challenge was the genetic contributions to the more common disorders, so 
that was the background.115 We also have to remember that leading up to 1990 
when the Human Genome Project started, with its 15-year projection, there had 
112 See page 11.
113 See Malcolm et al. (1991).
114 Professor Marcus Pembrey wrote: ‘To date over 50 genes in the human have been shown to be normally 
imprinted in a parent-of-origin specific manner, so only a single copy is active. In some the paternal copy 
is silenced, in the others it is the maternal allele that is silenced. Many imprinted genes are involved in fetal 
and early growth and development (e.g. insulin growth factor 2), so they are potentially very important 
in the ALSPAC study. Imprinted genes, discovered in the mid-1980s, are a classic example of epigenetic 
regulation with gene silencing by DNA methylation rather that DNA sequence change. It is now well 
established that DNA sequence is complemented by epigenetic information including DNA methylation 
and histone modifications to determine gene expression.’ E-mail to Ms Caroline Overy, 1 January 2012.
115 For developments in human genetics, see the Wellcome Trust Portfolio Review (2010): 73–80. 
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been a lot of discussion about whether it would be useful or not.116 The Human 
Genome Project was a non-hypothesis-driven study par excellence.117 Quite a bit 
of that battle for a broad, non-focused approach for the geneticist had already 
been won, you see, although we were coming from slightly different positions. 
What happened was that I got involved in discussing the requirements for blood 
samples and it all hinged on the cell lines. As I’ve explained, by the summer of 
1989 we’d got Porton Down on board, and so it was a question of putting in 
grant applications for cell lines to the MRC and Wellcome Trust. I can give 
you a whole list of them,118 and so on. I was encouraged to put something in 
but they were never funded. So that opportunity to get cell lines at birth was 
missed, but we were going to collect blood later as well. The reason why we were 
emphasizing the cell lines at that time was because I really felt that this might be 
the only window of opportunity in which to get enough DNA because of the 
ethical issues. Knowing that the techniques were going to improve over the next 
10–15 years, one wanted to be sure that one had enough DNA in order to do all 
the genetic studies. Imagine if the ethical climate had moved the other way, and 
we were forbidden from taking blood samples from children other than for their 
clinical needs. There were all sorts of factors for the reason we wanted to get the 
cell lines. We failed to get the cell lines for a decade, so we had to then get the 
consents linked to the samples that had been collected, so we were allowed to 
do DNA analysis. Before that it was a question of what sort of DNA-banking 
we should do. So I asked around, you know, 15 000 or 14 000 is a very large 
number. I seem to remember I went to Bob Williamson at St Mary’s119 because 
he was somebody you would go and talk to about these things. He said, ‘Well, 
I don’t know why you’re coming to me. You need to go to Sue Malcolm, the 
116 See, for example, Pembrey (1990).
117 For an introduction to the Human Genome Project, see Fletcher and Porter (1997), and the main 
Human Genome Project information website at www.ornl.gov/sci/techresources/Human_Genome/home.
shtml (visited 1 February 2012).
118 Professor Marcus Pembrey wrote: ‘Two examples of failed grants. 1) Medical Research Council – Pembrey, 
Marcus; Golding, Jean. “A cell line resource for genetic analysis within the ALSPAC cohort study” 1990 for 
5 years; 2) Action Research (S/L2131) – Pembrey, Marcus; Golding, Jean. “A cell line resource for genetic 
analysis within the Longitudinal Study of Pregnancy and Childhood based on the population of Avon 
(ALSPAC)” 1991 for 5 years.’ E-mail to Ms Caroline Overy, 26 February 2012.
119 Professor Bob Williamson was professor of molecular genetics at St Mary’s Hospital Medical School, 
Imperial College London (1976–95) after which he moved to the University of Melbourne as director of the 
Murdoch Institute and professor of medical genetics. He retired in October 2004 and is currently honorary 
senior principal fellow and professor at the University of Melbourne.
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people who are running a clinical service. They may not be doing that number 
of DNA extractions, but no one else knows anything better about that.’ I think 
it was about 1990/1. I already knew of course that Linda Tyfield was running 
the clinical molecular and genetic service in Bristol, and that the University of 
Bristol itself had no academic department of human or medical genetics, rather 
unusual for a medical school.120 So I enlisted the help of Linda, to start the ball 
rolling once we got a grant that allowed us to extract DNA.121 
Peckham: Did you find it easy to get consent from the parents to look at 
the DNA?
Pembrey: I was very involved in the wording of the explanation that was given 
to the mothers about their blood samples, and it said that we would look at 
their genetics; both theirs and the child, but there was no specifying of which 
genes. Perhaps we’ll come back to that under the ethics section at the end of the 
afternoon because that’s a big story.
Peckham: This was an issue in the Millennium cohort when oral samples were 
collected. The parents had to be informed that this was not for DNA testing 
because if it was assumed that samples were used for this purpose parents would 
not consent. 
Pembrey: That was not our experience.
Peckham: You were right in predicting that might have happened.
Pembrey: On the whole, about 70 per cent of the children in the clinics would 
give a sample for DNA and then at the next clinic, two years later, it would be 
a different 70 per cent. So in the end we got up to quite large numbers.122 But 
to do it chronologically, and go back to the early days; it was a real patchwork. 
There was a DNA extraction service in Southmead, Bristol, and then the rest 
of the DNA backing was organized at the Institute of Child Health in London, 
because there wasn’t an equivalent place in Bristol. 
120 For the development of clinical genetics as a major medical specialty in Britain, see Harper et al. (eds) 
(2010).
121 See page 60. Professor Pembrey wrote: ‘A two-year grant was gained from the Medical Research Council 
(£90 000) from 1 February 1995, to J Golding, S Humphries, I Day, M Pembrey, L Tyfield and C Pennock: 
“Can genetic variation explain Barker’s observations concerning fetal growth and adult coronary disease?”’ 
E-mail to Ms Caroline Overy, 1 January 2012.
122 See Jones et al. (2000).
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dr Linda tyfield: I don’t really know what more I can add to that. Perhaps I 
can say something about the historical context of molecular genetics in Bristol. 
One point worth making is that we’re talking about the early 1990s here, 
and up until about 1985, in the UK, there were only a few major molecular 
genetics laboratories that were combining research, a good deal of research, and 
clinical service work. One was at the Institute of Child Health in London. From 
about 1985 onwards there was a great burst of local molecular genetics service 
laboratories serving what were then Regional Health Authorities and some 
of these were incorporated into existing local pathology service laboratories, 
such as clinical chemistry or cytogenetics laboratories; others were separate 
departments.123 In 1988 I set up a molecular genetics service laboratory in the 
clinical chemistry department at Southmead Hospital where I had previously 
been based. There we were in 1991, taking on a very exciting project of 
extracting DNA from 15 000 samples for ALSPAC when we were still only 
getting a couple of thousand patient samples a year from the clinical geneticists 
for specified genetic disorders. We have been concentrating at this meeting 
today, and quite rightly, on the collection of samples and the inter-relationships 
between collectors and the mothers and children in the clinics, but one thing 
that we haven’t mentioned yet is the hard work of another group of people 
– the computing department of ALSPAC. Once the samples were collected, 
identifying labels were put on those samples, and somehow there had to be a 
foolproof mechanism to connect a specific sample taken from a specific person 
at a particular time with all the laboratory data that was eventually going to be 
generated from that person. If there was an error in the link, the data could be 
flawed. ALSPAC’s computer department had an identifying numbering system 
which incorporated check digits, rather like our credit cards with the three 
numbers on the back, that would pick up any transcription errors. The samples 
were brought to us at Southmead Hospital, from the freezers at United Bristol 
Healthcare Trust (UBHT) or the Children’s Hospital, by various members of 
the ALSPAC team. The identifying numbers of the samples were originally 
123 Dr Tyfield wrote: ‘Throughout the 1970s, 1980s and 1990s when there were Regional Health Authorities, 
monies were top-sliced for specialized laboratory services that were regionally based.  Originally these 
would have included biochemical genetic and cytogenetic services and samples would have come from 
clinical specialities such as obstetrics and gynaecology, paediatrics, neonatalogy etc.  Clinical genetics was 
another speciality with regional service responsibility and it was in the mid-1980s that molecular genetics 
laboratories were also included as part of regional specialist services.  Originally funding was made available 
from regional budgets through top-slicing for these regional services. Thereafter the funding process became 
more complicated.’ E-mail to Ms Caroline Overy, 11 December 2011.
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entered manually into our ALSPAC-linked computer, and we eventually used a 
barcode reader. In the beginning there were a number of things we had to test, 
particularly in relation to the procedures for extracting and aliquoting the DNA. 
This wasn’t as simple as sending a biological sample to a laboratory, putting it 
into an auto analyser and getting the results out. Not for DNA extraction and 
genetic analysis at that time, anyway. The gold standard for DNA extraction 
was the phenol-chloroform method.124 This was a lengthy, very labour-intensive 
technique and required several transfers from one tube to another, something 
that could readily lead to a source of sample mix-up. We had to have checks 
from a second person at every transfer stage of the process. Although this 
method was very time-consuming, the reason we stuck with it for so long was 
that it gave the best quality DNA and the longest lasting high-quality DNA. 
There were some extraction kits that were commercially available, which yielded 
perfectly adequate DNA from a fresh blood sample that was suitable for patient 
analysis in a local service laboratory where only a few genotypes were necessary 
to provide a clinical result. We needed a technique that ensured a high yield 
of high-quality, stable DNA, so that years later someone could still go back 
to these samples and carry out genetic analyses with the assurance that there 
would be reliable results. The next step was the quality assurance in transferring 
aliquots of the extracted DNA into multiple-array 96-well polymerase chain 
reaction (PCR) plates for distribution to our collaborators for genotyping.125 We 
included a number of samples in duplicate or triplicate in each 96-well plate in 
order to ensure the analysis of each plate was done in the correct orientation and 
that the results were reproducible.126 Sue Ring may want to say more on this. 
124 For the phenol-chloroform method of extracting DNA, see Chomczynski and Sacchi (1987, 2006); 
Puissant and Houdebine (1990). 
125 Dr Linda Tyfield wrote: ‘Collaborators were individuals in research laboratories who were exploring the 
possible relationship between certain genotypes and particular phenotypes, e.g. the association between 
variation at an individual locus and the susceptibility to, or potential for, developing a particular condition.’ 
E-mail to Ms Caroline Overy, 15 February 2012.
126 Dr Linda Tyfield wrote: ‘Some of the blood samples that were brought to us had been stored (frozen) for 
some time and it is almost certain that there would have been some degradation of the DNA during the 
initial period of storage. The phenol-chloroform method enables extraction of long, intact DNA as well as 
shorter, degraded strands. At the time we started extracting the DNA, PCR (the polymerase chain reaction) 
was in use everywhere. This is an ingenious technique whereby millions of copies of a particular part of the 
genome could be made in a tiny tube thereby making it possible to examine/analyse the DNA sequence in 
that specific area. A great advantage of PCR is that really top quality DNA is not always needed (although 
it certainly is an advantage) at the beginning of the reaction because the aim is to amplify a specific area of 
the genome.’ E-mail to Ms Caroline Overy, 20 December 2012. 
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000
62
ring: I was first employed as a post-doc on the first major DNA-banking grant 
at the end of 1996 in Linda Tyfield’s lab. I’d come from a genetics research 
background and I think one of the most important things that happened in 
the development of the DNA bank was that it was set up in a clinical service 
laboratory. I learned an awful lot from working in Linda’s lab, and also with 
Richard Jones, regarding the quality control steps that we needed to put in place 
to have a DNA bank that can still be used this far in the future. I think that was 
one of the crucial things; it wasn’t just seen as a finite research project, it had 
the long-term forethought to use the appropriate quality control procedures. 
As Linda said, we had to try several different methods to try to work out which 
DNA extraction method was best to use. One thing that Linda didn’t say in her 
summary was that one of the problems was that, by the time I was employed, 
the samples were already seven to eight years old. The commercial kits available 
at the time were good if you had samples that were relatively recent. I’d test kits 
out on test blood that was two months old, and then move over to the precious 
ALSPAC samples, and it just wouldn’t work because they’d been in storage 
for too long. In fact, in the laboratory, we’re still using phenol-chloroform 
extraction if we’re extracting samples that have been in the freezers for a long 
time. We had tracking systems in the lab, we started using barcodes from the 
seven-year clinic.127 Regarding the strategy for setting up the bank: we started 
127 See pages 60–1. 
figure 10. robobanker robot. in 2003, ALsPAC acquired two robots to 
immortalize cell lines.  they were named by cohort members, the ‘germinator’ 
which grew cells and ‘robobanker’ (pictured) which stored them.  
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by extracting DNA from cord blood, but that blood was collected in heparin 
anticoagulant and, at the time, this was problematic as heparin inhibited PCR 
in the genotyping processes. That’s not an issue any more,128 but back then it 
was, and so we had to rethink the whole strategy of which samples to use first. 
Therefore when I first started we were going to create the children’s DNA bank 
first, but then we had to put that on hold and move to the mothers’ samples, 
which were collected in ethylenediaminetetraacetic acid (EDTA),129 and wait 
until the seven-year clinic to start the children’s collection. So there was quite 
a lot of rejigging of plans due to the state of the samples at the time. When the 
samples left our laboratory they were taken to Richard in London to process, 
and at this point I’ll hand over to Richard.
Jones: One of the interesting things at an early stage was trying to assess how 
the identity of individual samples would be preserved. I think it would be true 
to say that we discovered that people are very bad beyond numbers in the tens 
or hundreds, in keeping track of what they’ve done to a particular sample. The 
beauty of moving to a robotic system is that, unlike a person, a robot does what 
you tell it to do and it does it exactly, even if you’ve got it wrong.
What we were doing was taking an industrial pharmaceutical way of dealing 
with large numbers of samples and learning how to work these systems and 
put them in a research context. I think the interesting thing was how the idea 
of using robotics in a university study seemed to be quite foreign to people, 
whereas, in fact, if you looked at what was happening in industry, this was 
commonplace and being used extensively. It was at that point also that we 
started to widely use barcodes that prevented samples from being muddled up. 
There’s nothing much more to say about that really except that it was good fun. 
[Laughter] 
Peckham: When was the DNA available for researchers? How long did this 
process take?
Pembrey: Well, I think we ought to backtrack a little bit here: obviously there was 
the question of extracting the DNA, but the whole question of banking it was 
something that we had to address before we could put in the big strategic grant 
to the Medical Research Council. This was for £1 million in order to employ 
128 Dr Sue Ring wrote: ‘Methods have been developed which use less DNA therefore the effects of heparin 
can be overcome by diluting the samples.’ E-mail to Ms Caroline Overy, 30 January 2012.
129 Dr Sue Ring wrote: ‘Ethylenediaminetetraacetic acid (EDTA) is an anticoagulant used as heparin is used 
to prevent blood clotting.’ E-mail to Ms Caroline Overy, 30 January 2012.
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people like Sue Ring and others, and actually fund the robots.130 I asked around, 
and there wasn’t much expertise on this that I could find at the Institute of Child 
Health, and I was quite concerned about it. Then it happened that the job in 
clinical pathology was vacant at the Institute and Great Ormond Street. Doug 
Higgs, who is somebody who worked with David Weatherall131 told me that 
Richard Jones was in the market, as it were, and indeed he was appointed. What 
particularly interested me about this episode was David Weatherall, who had 
written a letter to me right at the beginning when I approached him in 1988/9, 
saying what a wonderful idea ALSPAC was and so forth and so on, although 
we had singularly failed to get any money for the genetic aspects and the DNA 
bank at all. In 1992, I think it was, I had to go up to Oxford on a site visit: they 
were on the receiving end and I was chairing the site visit.132 I said to David: ‘Oh, 
could I have a word before we get started at 9 o’clock?’ And he said, ‘Yes, come 
into my office,’ and before I could say: ‘What do you think of Richard Jones 
because we’re thinking of approaching him to come to the Institute?’ he said, ‘I 
know what you’re going to talk about, you’re going to talk about ALSPAC’ and 
was trying to explain why we hadn’t got any funding.133 So anyway, Richard came 
to work with us and it was a long old haul to get the robots to work.
Jones: The problem was not primarily getting the robots to work, the problem 
was finding out how much DNA we had in each sample, and how much we 
were giving away. The reason for that is that people had believed that they were 
measuring the concentration of DNA samples in the past, and in fact they 
weren’t, because DNA is so difficult to deal with. Those of you who have dealt 
with it know that it’s gloopy, and moving accurate quantities of gloopy material 
around is almost impossible. We were being pressured by potential collaborators, 
who said: ‘What’s the delay? This is a very simple business.’ They didn’t know 
130 Professor Marcus Pembrey wrote: ‘A four-year grant from the Medical Research Council (£1 009 207) 
from 19 May 1997 to M Pembrey, J Golding, H Simmons, L Tyfield, R Jones for development of a DNA 
resource for genetic studies within ALSPAC.’ E-mail to Ms Caroline Overy, 1 January 2012.
131 Professor Douglas Higgs is currently professor of molecular haematology at the University of Oxford and 
director of the MRC Molecular Haematology Unit; Professor Sir David Weatherall was Regius Professor of 
Medicine (1992–2000) and is retired honorary director of the Weatherall Institute of Molecular Medicine 
at the University of Oxford.
132 Professor Marcus Pembrey wrote: ‘This was a site visit for renewal of an Action Research grant to David 
Weatherall’. E-mail to Ms Caroline Overy, 1 January 2012.
133 From the Wellcome Trust; Professor Sir David Weatherall was a governor of the Wellcome Trust from 
1990–2000.
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that it was not a simple business. We knew that it was not a simple business, and 
it took us some time to get to the point where we had confidence when people 
asked us for a sample of DNA, that we could give them a certain quantity. The 
problem is now well recognized, but has been quite chronic. I have to confess, 
though, looking back on it, that I sometimes wonder that, given the difficulties 
of measuring DNA concentration and attempting to aliquot it out in constant 
amounts for collaborators, whether in fact had we simply put a drop in the 
bottom of a tube, not knowing how much was there, and distributed that, I’d be 
interested to know what the comparison was and the quality of genetic results 
from the totally untouched set of samples, compared with those to which we’d 
tried our utmost to get the concentrations even and equal. I don’t know the 
answer to that, but sometimes you have to ask these questions.
Pembrey: We’re getting to answer your question as to when the DNA was 
available. What happened was that we had one project grant from the MRC in 
1994/5, in which we were going to start doing DNA extractions in Linda’s lab. 
But in order to get the strategic funding for DNA-banking from the MRC, we 
obviously needed a national advisory committee. So in 1995 we formed a genetics 
advisory committee, and I was chairing it. Linda, of course, was on it; there was 
John Todd; Alex Markham, who was going to be here today; Ian Day, a technical 
adviser; Jean Golding; Steve Humphries from UCL; and Richard Jones; and 
David Baum attended some of the early meetings.134 At the first meeting of that 
group, one thing we had to consider was applications for studying a particular 
gene; we didn’t want, in those days, a lot of duplication of genetic analysis. Both 
John Todd and Steve Humphries wanted to study the insulin growth factor 2, 
and so the first time we had a fight on. There was only one gene they wanted 
to study and it was the same one. [Laughter] But we persuaded them to sort it 
out between themselves. In those days we would only be studying the ‘Children 
in Focus’ samples, and we would receive applications for the genes that people 
wanted to study and then discuss them gene by gene in this committee, which 
met several times a year. The first paper eventually got published in 1998, so it was 
134 Professor John Todd was then senior scientist, at the Wellcome Trust Centre for Human Genetics, 
Nuffield Department of Surgery, University of Oxford (now professor of medical genetics, Cambridge 
University); Professor Sir Alex Markham has been professor of medicine, Leeds Institute of Molecular 
Medicine, since 1992; Professor Ian Day held a British Heart Foundation Intermediate Fellowship at UCL 
Medical School (now professor of molecular and genetic epidemiology, Bristol Genetic Epidemiology 
Laboratories); Professor Steve Humphries was at the Centre for Genetics of Cardiovascular Disorders at 
UCL Medical School (now British Heart Foundation professor of cardiovascular genetics at UCL). 
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a long time from when the DNA was originally taken.135 Today, of course, the idea 
of discussing gene by gene what you were analysing would be complete nonsense. 
Peckham: What did you charge them for the samples?
Pembrey: This is a very good point because we didn’t have full funding at this 
time, we hadn’t got to the stage of any core funding from the Wellcome Trust, 
for example, so we had to try and claw back some money. It was quite a large 
amount; I can’t remember – Sue Ring, do you remember? A lot of people were 
put off from doing the study because they would get a thousand DNAs but it 
would cost them, you know, £11 000 or £12 000, something like that.136 
Jones: I was going to comment more given that Marcus has gone into the 
business of dealing with collaborators. It is interesting to look back to that point 
where each individual collaborator would have one or a few genes in mind, and 
was particularly keen that they should have a sample of DNA in their hands. 
So their view of the resource was as a source of actual, physical DNA and that 
participating as a collaborator was to actually go away with that DNA. I think 
then, over time, the idea that there would be a pool of genetic information, 
independent of the actual samples, which was itself a paper resource, slowly 
took over; potential collaborators became far more relaxed about whether they 
were doing the actual DNA analysis or whether someone else was going to 
do it, and they would be given the information. That has probably moved on 
steadily now, and I think George Davey Smith, from what you were telling me 
today, we have now reached the point where DNA is not being handed out 
particularly to individuals because you’re collecting the information across the 
whole genome.
davey smith: Yes, most of the requests now are for genetic data rather than for 
samples of the DNA because we have genome-wide data; 600 000+ markers on 
virtually everyone on whom we have samples.137 Thus the requests for DNA are 
fewer. There are requests for samples for methylation (epigenetic) analysis,138 
of course, which I guess wasn’t something considered earlier on. Marcus could 
135 Dunger et al. (1998). 
136 Professor Marcus Pembrey wrote: ‘The figures for “claw back” on DNA-banking costs from non-
Wellcome Trust or MRC-funded projects ended up in 2003 as £10 000 for 1000 DNAs and £40 000 for 
10 000 DNAs.’ Note on draft transcript, 26 September 2011.
137 For example, the ALSPAC genome-wide data is included in Paternoster et al. (2010). 
138 For further information on epigenetics see Relton and Davey Smith (2010). 
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say whether this would have been a possibility all those years ago. For us today, 
bioinformatics and data handling issues are key. 
Peckham: I think the whole issue of the data linkage, or the linkage of genetic 
information to the general ALSPAC database is interesting. Are you talking 
about analysis of the samples with linkage to the information in ALSPAC, or 
just analysis of the samples when people are requesting samples from specific 
groups within the cohort? 
Jones: It’s retrieving the genetic data from the actual DNA samples. That’s what 
I’m calling analysis. 
Peckham: Yes, but they wanted that without any information from the ALSPAC 
cohort? Because that’s another issue, isn’t it?
Jones: Yes. There are perhaps some questions you can ask about that.
golding: We had a very complex system whereby every set of data, whether it 
was a questionnaire or a biological sample of the DNA, had its own number, 
and the number had check digits at the end, so that if you mistyped it, it would 
show as an error. Then there was a complex set of programmes that would link 
these things together. You wouldn’t be able to do it if you came across one data 
set and another yourself, so that applied to the DNA in just the same way as 
anything else; at least that’s my understanding of how it worked. But that was 
thanks to our computer team, which worked all the hours God gave them.
Jones: The interesting development was from individual collaborators very 
much wanting their own bit of DNA from which they could extract the genetic 
data themselves, and so on, over a course of, what are we talking about, ten 
years? In ten years we’ve arrived at a situation where it’s essentially an industrial 
process, generating data efficiently for everybody, and not bit by bit. The 
important thing is to contrast that achievement with the other part, the blood 
samples, the plasma, or the serum or whatever you’ve stored, where there had 
always been promise of a similar kind of development, but as far as I know, 
this has hardly happened; which means that there is an enormous stress on 
biological sample collection outside DNA, in the sense that it’s still accessed by 
individuals who don’t necessarily have the most efficient way of extracting their 
biochemical or biological data from the sample. Those samples are finite; you 
can’t amplify them as you can DNA, and they are constantly being used in a 
relatively inefficient way. It’s very hard to resist the inefficient use because each 
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inefficient use is linked to a grant and each grant is bringing money to the study. 
There has been no real rational development in the same way as there has with 
genetics in the whole field of other biological data. 
Pembrey: Could I just add two points? The first is to illustrate the hand-to-
mouth way in which we worked. When we were able to get the £1 million DNA-
banking grant at the end of 1995/beginning of 1996, a large bit of the money 
was for the computing backup, actually for the DNA database and so forth. 
But the situation was that we were getting the DNA at the seven-year clinic 
and there wasn’t any money for the computing needed for the appointments for 
the seven-year old clinic. So quite a bit of the DNA money was used for that 
purpose. Quite rightly, because the idea was to get DNA at the end of it. 
Another point is that at a fairly early advisory committee of one sort or another, I 
remember George Davey Smith saying that we have to get 3 per cent duplicates; 
that with people coming through the clinic we have to get 3 per cent who would 
go through it all again. The issue was whether they would give blood samples 
again? George said, ‘Yes, of course, otherwise you can’t know A, B, and C.’139 I 
remember this being discussed in the Law and Ethics Committee, whether to 
take a second blood sample or not. In fact, it has proved absolutely vital, very 
useful, particularly in the early days, for validating whether labs were able to do 
genetic analysis. We had this check – they wouldn’t know, of course, which were 
the duplicates.140 So those two points helped launch and maintain the standard 
of the DNA-bank.
davey smith: I was going to say something else, but I remember having to go 
to the Ethics Committee to present this, as being a very scary occasion, but we 
constantly have to report the coefficients of variation for such measures in papers, 
so it has been useful.141 One further point, which doesn’t really relate to the history, 
but on Richard’s point: there is this promise of proteomics, metabonomics, 
measuring everything in a tiny blood sample.142 The technology is still developing. 
139 Professor Marcus Pembrey wrote: ‘The 3 per cent figure was arbitrary, it was just that we needed a 
reasonable number of repeat analyses on the same subject to judge the reproducibility of the methods and 
procedures used.’ E-mail to Ms Caroline Overy, 26 February 2012. See note 141. 
140 For an example of validating a laboratory with duplicate samples for kidney dialysis, see comments made 
by Dr Felix Konotey-Ahulu in Crowther et al. (eds) (2009): 41–2.
141 For a report of these coefficients of variation see, for example, Donald et al. (2010).
142 Professor George Davey Smith wrote: ‘Proteomics and metabonomics are methods that measure a very 
large number of factors in small samples of blood or urine. For this approach see, for example, Chadeau-
Hyam et al. (2011).’ E-mail to Ms Caroline Overy, 9 December 2011.
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The problem with those technologies at the moment is that they don’t give people 
what they want because they essentially give you the size of particles in the blood, 
but they don’t tell you how much there is of this particular analyte or that analyte. 
But when we’re down to limited samples, we certainly have a policy of not allowing 
those to be used for a single or a couple of analytes, but saving samples in the belief 
that eventually the technology will develop to the level where they can produce the 
type of useful information on very large numbers of particular analytes. 
Jones: I think the DNA example, the genetics example, is just an example of 
how it was at the beginning, although you had to wait a long time for a grant 
application to work; when there was money, the money was very generous by 
comparison with any other part of ALSPAC. I was a beneficiary of that. It goes 
to show that the amount of effort and fragmentary financing of a study creates 
enormous problems and inefficiencies. When you suddenly get, what was it, £2 
million or something, when you magically get funded on an adequate level to do 
something, the gains in efficiency are so large. I think the only block is the fear of a 
white elephant, isn’t it? There’s an enormous cost to that and I think ALSPAC has 
always managed to get through that in piecemeal fashion, but at many stages it 
would have been so much more efficient if someone had had the courage of their 
conviction, in giving us that £2 million, when the children were aged five or six. 
Peckham: It’s extraordinary really that the momentum was kept up for so long 
until you were able to reach that stage.
Jones: Indeed. Well, that’s down to Jean, I think.
golding: Down to everybody.
Peckham: Can I ask you, Jean, about the broader issue of collaboration because 
data access and collaboration is very important? I am aware of recent changes, 
but if researchers want access to your data, how did you deal with that? Was it 
a big issue for you? I know it was perceived as an issue by some outside, and it 
must have been difficult for you given your resources and support.
golding: The issue was over finances, and people who had worked with the big 
national cohort studies were used to getting data free from those studies,143 which 
143 Most cohort data can be accessed by registering with the UK Data Archive, which is administered by the 
Economic and Social Data Service (ESDS) at the University of Essex, www.esds.ac.uk/longitudinal/ (visited 16 
November 2011). ESDS Longitudinal has undertaken a data audit of ALSPAC in preparation for improved 
access for secondary users and, from June 2009, a set of sampler data files produced by the ALSPAC study team 
was available at www.esds.ac.uk/findingdata/snDescription.asp?sn=6147 (visited 16 November 2011).
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was natural because the data had been paid for and archived so that they could 
be obtained. We asked for collaborators to raise some money towards our costs 
of collecting the data, and a number of people found that a big issue. We were, 
we thought, always being very collaborative and always looked at proposals; it 
was the steering committee or the scientific advisory committee that considered 
them all, and made suggestions or, very rarely, turned any down. One of the 
things one had to look at was the ethics as well as the science. 
Peckham: Did the research councils accept that? If people put in an application 
to do a study, did they accept the fact that payment was included in the proposal?
golding: They did eventually. It took the ESRC until the 2000s to do so. The 
MRC accepted it much earlier. The Wellcome Trust finally accepted it.144 But 
we were asking for about £40 000 per grant, which for running the study was 
great because it wasn’t tied to any particular thing, so you could plug a hole or 
two with it. 
Peckham: So now with more adequate funding, has access to data and 
collaboration been made easier? Is that right, George? 
davey smith: Yes, and it also became a condition of funding on a proper basis, if 
you like. As you are very well aware, in this building of the Wellcome Trust (215 
Euston Road), they particularly drove the line that when they were funding 
studies like ALSPAC they were funded as resources rather than as single studies 
based in single places. That is now a condition of the funding. But there are 
still extensive amounts of funding raised through collaborative activities, in 
particular activities that fund additional aspects of data collection, so that the 
core funding support funds a skeleton operation collecting rather minimal levels 
of data, and certainly from the last 15+ and 17+ clinics, more of the funding 
has been the additional funding than has actually been the core support. That 
funding has to be built in in advance to support the actual collection of the 
data; we are not going ahead to collect the data and then obtain funding for its 
use. I think if I ran up an overdraft of £1 million at Bristol University today, I 
would come in to find my desk emptied and be escorted off the premises. 
Peckham: I’m sure you would. Would anyone like to say any more on the genetic 
aspects? We’ve got a few more minutes, and I would like to go back to the issue 
of governance because I think this has been a terribly important aspect, an aspect 
144 Professor Jean Golding wrote: ‘As far as we can tell, the Wellcome Trust started allowing a fee for ALSPAC 
in 1998, and the MRC in 2000.’ E-mail to Ms Caroline Overy, 20 December 2011. 
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000
71
that has, as you mentioned, informed Biobank and a lot of the other studies; it’s 
been a real example. Can we go back and discuss it a bit more fully? Also the 
changes in ethics committees and how they function. You’ve seen those changes 
while trying to retain control of the study. I think the tension is quite interesting. 
Mumford: I’ve been associated with the Ethics Committee for 21 years; I was 
there at its first meeting, but I’m still convinced that the most important period 
in the life of that committee was the gestational period, that is the period before 
we all arrived. In my view it’s quite remarkable that the committee came to exist 
at all, particularly with the very broad mandate that it had. To understand that 
you have to go back, as you say, to look at the state of the ethical regulation, of 
the legal regulation, of medical research 20 or 25 years ago. I dug out a couple 
of old textbooks of medical law. Let me read one to you: this one was by Mason 
and McCall Smith, who has, of course, become better known for other sorts of 
writing, but he is a wonderful writer of medical law as well. This is a quotation 
from the second edition (1989):145 
It is now almost mandatory for hospitals or health authorities to establish 
‘ethical committees’ whose function is to sanction each experimental 
project before it is launched. Despite the fact that the setting up of 
committees was advised as long ago as 1967, their composition and 
remit is still not firmly based. Their existence is, however, becoming 
more widespread.146
The book goes on to question whether there ought to be lay members on such 
committees. In another paper written around the same time the author had done 
a survey of ethics committees, and reported that the membership ranged from 
anything between 3 to 15 members, and the meetings from anything between 
never to once a month.147 I know that ethical scrutiny in one university with 
which I was associated, was done by having proposed projects sent from the 
145 Mason and McCall Smith (1989): 256. Alexander McCall Smith is now more widely known as a writer 
of fiction, for example, The No. 1 Ladies Detective Agency series. 
146 Following the World Medical Association’s Declaration of Helsinki (ethical principles for medical research 
involving human subjects) in 1964 (see Riis (2001)) and the publication of Pappworth’s Human Guinea Pigs 
(1967), the Royal College of Physicians recommended that all research be subject to ethical review (Royal 
College of Physicians (1967)). See also Reynolds and Tansey (2007). 
147 See Nicholson (ed.) (1986). 
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000
72
medical school to the law school; the law professors then, as part of their pro bono 
work, simply went through the papers, gave an answer, and sent everything back 
to the medical school. So ethical scrutiny was haphazard, and, if you look at the 
‘law professors versus medical professors’ example, it was a bit adversarial.148 
Of course, the whole area of the regulation of medical research grew out of 
the experiences, the atrocities of Nazi Germany, the Nuremberg trials and 
the Nuremberg Code.149 It’s a bit of an unfortunate way to start, but I think 
that relationship did mark, and probably still does mark to some extent, the 
relationship between ethics committees and people trying to do medical research. 
At the same time, 20 years ago, possibly even more than now, there was a real 
fear, I think, among the scientific and medical community about what they called 
‘defensive medicine’. There were a lot of articles being written about the threat 
coming from the US of this imposition on clinical practice, and also on medical 
research.150 So you got the haphazard, the adversarial, and then along comes 
ALSPAC. There was a lot of writing done at the time, in the 1980s, about good 
ethical practice. We’ve talked about the guidelines from the British Paediatric 
Association (Royal College of Paediatrics and Child Health since 1996), the 
Royal College of Physicians and so forth.151 I still think it’s groundbreaking that 
the founders of ALSPAC had this idea, not of submitting reluctantly to scrutiny, 
but actually asking for help and collaboration. That’s really the outstanding thing 
about the beginning of this committee: the sense that having an ethically ideal 
study was every bit as important as having a scientifically ideal study. 
148 Mrs Elizabeth Mumford wrote: ‘It is the idea of scientists having no participation in the ethical scrutiny 
and the slight rivalry between law and medical faculties – it’s always easier to grumble about the results when 
it’s “them vs us”.’ E-mail to Ms Caroline Overy, 11 January 2012. 
149 ‘The Nuremberg Code was the first internationally recognized set of guidelines dealing specifically with 
non-therapeutic human experimentation.’ Hazelgrove (2001): 559. 
150 Mrs Elizabeth Mumford wrote: ‘It’s hard to know the extent to which this ever really did or does happen 
in the UK. Certainly there have been dozens of articles about it in the US – mostly about its financial cost. 
The fear of it spreading was certainly widespread, probably more so in the 1980s than now. The term is 
intended to refer to unnecessary tests and procedures done in order to protect clinicians against potential 
legal action. Clinical judgement might suggest that there was no need for the procedure, but nothing is ever 
certain in medicine and so the fear that the unlikely might materialize, and the untested/untreated patient 
complain and sue, might lead to something being done “just in case”. Such procedures may, of course, also 
be detrimental to the patient, if they themselves carry risks. As for particular examples, caesarean section 
is one commonly cited, as are CT scans for every head injury. But are these really examples of defensive 
medicine, or just an example of our risk-averse culture?’ E-mail to Ms Caroline Overy, 18 February 2012.
151 See note 110.
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My own involvement with ALSPAC began when I got a letter from Professor 
Michael Furmston152 in the Bristol law faculty inviting me to come along 
and join the Ethics Committee. I was very excited; it was my first year as a 
lecturer, and this was a thrilling opportunity for me. I think the enthusiasm for 
that committee is the same sort of enthusiasm that marked the whole of the 
ALSPAC study. The fact that this committee was not just to be a reactive one, 
but a proactive one, something that other people have mentioned already, made 
it particularly interesting to be in at the beginning. I also think that some of the 
most interesting work done by the committee was done in the first year. As for 
the issues, if you look at the minutes of the first year, all the issues were there.153 
Michael Furmston began the first meeting by saying: ‘Now these are the things 
we’ve got to look at.’ He began with consent: consent to take part at all; consent 
to answer questions; consent to make use of biological samples. A year and a 
half on, that was the first issue that the committee had disagreements about.154 
It was the first time that we couldn’t actually reach a conclusion on the spot. 
We came back again and again to look at biological samples, and finally decided 
how we were going to get consent for them – the way in which that was going 
to be handled. So we looked at consent in that first meeting.
We also looked at confidentiality and talked about the postal questionnaires, 
and the interviews. It might have been at that meeting that we first came across 
a phrase which has come back again and again to haunt us; the statement that 
there was no way that participants’ names and the information they provided 
152 See note 71.
153 Mrs Elizabeth Mumford wrote: ‘In the minutes of the very first meeting, we outlined the issues of: 1. 
Consent (a) to join the study/fill in questionnaires/be interviewed and (b) to physical tests (e.g. blood, 
placenta); 2. Confidentiality; 3. Access to information – i.e. reporting of results and 4. Use of biological 
samples’. E-mail to Ms Caroline Overy, 11 January 2012.
154 Mrs Elizabeth Mumford wrote: ‘The problem was essentially that the best time for taking samples (i.e. 
when they were being obtained for therapeutic reasons in any case) was not necessarily the best time for 
obtaining consent to ALSPAC’s research. The consent might well be obtained months later. Samples taken 
early on would be of no use after a lengthy storage period, and it was much more efficient and led to 
better scientific research etc to batch them and do some preliminary work on them as soon as they became 
available. However, ALSPAC participants had been told at the outset that research would not be undertaken 
on their samples until they had given consent. The divergent points of view were as follows: some believed 
that there was no real problem as: (1) ALSPAC was just generating raw data, not really doing research yet; 
(2) what people were really worried about was confidentiality and that would certainly be respected; (3) it 
wasn’t even strictly necessary to obtain consent to use the leftover bits of tissue already taken for therapeutic 
purposes. On the other hand, others felt essentially that a promise was a promise – whatever the form of 
words.’ E-mails to Ms Caroline Overy, 11 January and 18 February 2012.
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could be linked. Right from the beginning we also considered the question 
of access to information; whether we were going to report things back to the 
participants. Gordon has already talked about some of the problems we’ve had 
and some of the conclusions that we reached as to how much information to 
give back.155 But all of this came up in the first meeting. 
The work of the committee has been not only interesting, it’s also been very 
enjoyable. In its early days I think that this was in large measure because of 
the personality of its first chairman, Michael Furmston. His style of easygoing, 
congenial leadership has, I think, been taken over by Gordon and David 
Jewell,156 who have subsequently been the chairmen. Michael Furmston is now 
the dean of a law faculty in Singapore; he retired from Bristol 12 or 13 years 
ago. If you haven’t met him, he is a man who is ‘larger than life’ in every way. 
He was twice dean of the Bristol law faculty, he was Pro Vice-Chancellor, an 
eminent scholar in contract and commercial law, areas of law miles away from 
this one. He is a barrister, a practising barrister. He would lead the meetings in a 
style, which I suppose is reminiscent of the development of the common law, so 
he’d do it by stories and anecdotes. Some of them were anecdotes about his own 
home life – quite a lot of them were – but his home life was rather interesting 
as well. He had ten children, plus about 22 dogs, and goats, and I believe some 
other type of small animal. They bred animals to show. He was a postal chess 
champion. He was an expert on the American Civil War and on cricket. To 
find him in his office you would first have to negotiate a sort of labyrinth of 
bookshelves. But he was enthusiastic, he was warm, he was encouraging, and 
he had a wonderful style of leading meetings. So it made it a very civilized, very 
enjoyable atmosphere in which to conduct some really very difficult business. 
I think that’s what made the committee such a success in its early days. Many 
people have remarked since then that this pattern of real collaboration has 
continued: collaboration amongst the members of the committee and with the 
study. We felt that we were working on this together to get answers that would 
be beneficial to the study as a whole.
Peckham: So it was much more than an ethics committee?
Mumford: Far more than that. We looked at individual projects as they came 
along, but we were looking far more to the future, thinking how we would 
155 See page 35. 
156 Dr David Jewell is the current chair of the ALSPAC Law and Ethics Committee; he was a senior lecturer 
in primary health care in the University of Bristol from 1987 to 1999.
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handle these issues and discussing things in that sort of broad sense. I think that’s 
what makes it quite different, and probably remains in some ways different, from 
almost any other ethics committee, although there are some which have followed 
in its wake. In the early days, I presented a couple of papers on the work of the 
Committee and people from other European countries would come up and say: 
‘This is really exciting. Nobody else does this.’ That distinction was the idea of 
the people who came up with the proposal for the committee in the first place.157
Peckham: So what is the situation now with the current ALSPAC, George, 
in terms of your relationship with the Ethics Committee given the other 
developments which have taken place around ethics more widely? Does it still 
have the same role, or has it changed?
davey smith: No, I think it has exactly the same role and David Jewell is the 
current chairperson. Obviously there has always been a sort of dual structure, in 
that there are what are now called the National Research Ethics Service (NRES) 
committees, and studies that involved NHS facilities or any invasive procedures 
such as taking blood or scans, etc., go to the NRES. There’s also the faculty 
ethics committee in the university, which the ALSPAC Ethics Committee works 
with, and we have discussions with people who are in different faculties who go 
through their ethics committees. So there’s a complex web of ethics committees, 
which, I think, reflects the fact that there is basically no single legal foundation 
for the role and function of these committees. The ALSPAC Ethics Committee 
certainly has had an absolutely vital role in the study.
Peckham: Have you had any disagreements with the national ethics committees 
in some of your decisions?
davey smith: I think disagreements would be the wrong term. Many things have 
been iterative. Marcus alluded to this earlier and, though it didn’t really come up 
in the discussion here about genetics, this was a big area. There were definitely big 
changes in perspectives regarding the ethical issues and around genetic analysis, 
when the earlier notions were that we got marker-by-marker approval, which 
has become unfeasible. Although it wasn’t in ALSPAC but in another study I 
was involved in running, our approach was to send frequent applications to the 
committee until this was realized as not to be sustainable. Then bodies such as 
the MRC started developing statements regarding appropriate ethical approvals 
157 Mumford (1999a and b). 
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with respect to genetic analysis.158 There was also a change in the gestalt around 
what genetic analysis was going to tell you as it started becoming clear that, with 
common genetic variants, the effect sizes were going to be small and were not 
going to have individual level implications. I think it would be wrong to put that 
under the heading as a ‘disagreement’, but it went through iterations where it 
went through the ALSPAC Law and Ethics Committee, back to our local LREC 
as it was then, and I was asked to attend them during that period, and decisions 
emerged. It didn’t appear to be a conflictive situation, but was a situation where 
the procedures needed to change, if you like, to fit both the technology and what 
had become known.
Peckham: The continuity in the discussions we’ve had has been very interesting 
–  how the study has grown and developed.
Mumford: I think in the early days we were considered quite tough. I think 
our standards were a little bit more stringent, and some researchers would say: 
‘Look, the LREC has approved this project. What’s wrong with you? Why are 
you so much more stringent in what you’re requiring?’ Looking over the early 
minutes that sort of response came up a few times.159
golding: I want to put on record that I found the Ethics Committee somewhat 
scary, but incredibly helpful. In retrospect, yes. But I could approach them with 
problems I’d had or a decision that I’d had to make quickly, and then we could 
discuss it afterwards and record what had happened and what should happen 
in the future. I found the whole thing was a positive support, in what were very 
hairy situations at times because things were moving so fast. 
Mumford: And you’d be there and we’d ask you: ‘Please Jean, can you explain to 
us what this is all about?’ There really was a sense of collaboration.
stirrat: Perhaps there’s one small area that hasn’t been picked up, which is an 
important one, and related to the interviewers who would be going out to homes. 
158 For the MRC ethics and research guidance, see www.mrc.ac.uk/Ourresearch/Ethicsresearch
guidance/index.htm (visited 20 December 2011); for the Wellcome Trust guidelines on ethical practice, 
see www.wellcome.ac.uk/About-us/Policy/Policy-and-position-statements/WTD002753.htm (visited 20 
December 2011). 
159 Mrs Elizabeth Mumford wrote: ‘I have one set of minutes that refers to Dr X (a collaborator who was 
a frequent visitor to the committee) who highlighted the difference between the local research ethics 
committee’s response to his proposed research (permission to test “spare” biological material without the 
consent of the mother) and ALSPAC’s response (no testing without the prior consent of the mother).’ 
E-mail to Ms Caroline Overy, 11 January 2012.
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000
77
On occasions they came across situations that distressed them, and indeed really 
needed to be reported: potential child abuse, these sorts of things. One of the 
things that we did early on in the Committee was to set down the criteria and 
the mechanisms through which it was ethical, legal and appropriate to bring 
those situations to the attention of the appropriate authorities. It was actually 
Jean, I think, and she might want to comment on that. That was important not 
only for the whole conduct of the committee and of ALSPAC, but for those 
interviewers themselves because it gave them backup. They actually felt they 
were supported.
golding: Yes, things were reported to me first and then I reported them to Alan 
who was the community paediatrician.
emond: One of the most difficult things in my involvement with ALSPAC was 
trying to balance my responsibilities as a clinician participating in safeguarding 
children in the NHS with my responsibilities to the study. I felt that ALSPAC 
had to adopt the same thresholds of concern as were current in clinical practice. 
There were a couple of occasions where it did result in the family withdrawing 
from the study, and that caused a lot of heartache, but I think my conscience 
is clear that, at the end of the day, we did pertain to the same thresholds that 
were around at the time. Again, over time, these thresholds have changed, 
and probably have got lower rather than higher, but ALSPAC did take these 
seriously. There were one or two quite worrying cases of neglect and abuse, 
and of mental health issues, that we had to take account of. These are not 
written up anywhere, but that did go on behind the scenes. I’m sure Jean had 
some troubled nights about these cases, because you were caught in a dilemma, 
because you knew if you blew the whistle the family would withdraw from the 
study, and on a couple of occasions we had to do that.
golding: I should point out that this only occurred where it was direct contact 
with the participants. Anything written in the questionnaires was not acted 
upon. That was always something that one could talk about with the Ethics 
Committee.
Peckham: Are there any other burning questions you think that we haven’t 
covered that you’d like to mention?
Birmingham: I took over from Elizabeth Mumford as secretary of the Ethics 
Committee. There’s just one thing that seems to me to be a bit of a problem 
with all ethics committees, whether it’s our own or the LREC as well, and that is 
consistency. It seems that it’s very difficult for them to be consistent. David Jewell, 
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our current chair with the ALSPAC Ethics Committee, talks about that now and 
it seems that we need to have some policies that are made and approved by the 
Ethics Committee, so it’s quite clear. There are a lot of areas where there isn’t a 
policy written for it, and it will come up two years, three years, four years later. I 
regard part of my job to look back and see what the committee decided and when 
this was talked about earlier? Things change: the gestalt of ethics changes.
Peckham: Can you given an example?
Birmingham: Of inconsistency?
Peckham: Yes, of something that might have cropped up.
Birmingham: Well, I can certainly give you a very good example of inconsistency 
from the LREC, where we put in an application to take blood from parents who 
accompanied the children to the clinic. Because we ran annual clinics, and we’re 
a 21-month cohort, there were two clinics running at the same time. So one 
application went in as part of a new application for this particular clinic, that 
we’d like to take the blood from the parents, along with all the other measures. 
The other was an amendment to a clinic already running. It was exactly the 
same paperwork, apart from the heading: Team Focus 1 or Team Focus 2, or 
whatever – they went to the same committee on the same day. One was approved 
with no comment; the other was not approved with a great long list of reasons 
why we couldn’t use blood from those parents without further ethical approval 
for each proposed analysis. That caused us huge difficulties. Three years later, 
George eventually managed to sort it out. We had this one set of blood that was 
collected at this particular clinic which we couldn’t use. You couldn’t just go 
back to them and say: ‘Well, hang on a minute. You’ve approved it here, but not 
here.’ It took three years to sort out.160 It was really frustrating.
160 Miss Karen Birmingham wrote: ‘Just to clarify, blood collection (with informed broad consent for future 
research) from parents accompanying their children to the ALSPAC research clinic for 12-year olds, was 
approved without comment. For parents accompanying their children to the very similar research clinic for 
13-year olds, using identical consent forms, the LREC stipulated that “... any proposed research involving 
this collection of DNA and cell lines thereof should be subject to further ethical review by the Research 
Ethics Committee as per MRC guideline. Approval in terms of this application is only for the collection 
and storage of these samples.” This was not only a misinterpretation of the MRC guidelines, but also totally 
inconsistent between the two clinics. The blood was taken and stored and not wasted, but it took a very long 
time before they agreed to us using the cell lines and DNA without gaining further consent.’ E-mail to Ms 
Caroline Overy, 9 December 2011.
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Peckham: Are there any other relevant topics that you feel are important? It’s 
been fascinating listening to the historical development of ALSPAC.
tansey: It really has. I’d like to thank you all very much for coming and telling 
us your stories, and actually shedding so much light on an important study. I’m 
very grateful to you all for coming and contributing. As I said at the beginning, 
we will be in touch with you throughout the rest of the procedure, going from 
this meeting to a published volume. I’d like to thank Lois Reynolds and Caroline 
Overy for walking around so much with the microphones today. And, of course, 
the Wellcome Trust because they fund our work. We are also very grateful to 
the Wellcome Trust for allowing us to meet here in their headquarters, and for 
funding this ‘Witness Seminar’ project. I’d particularly like to thank Catherine 
for her excellent chairing; getting us to a glass of wine absolutely on time, 
but very relevant and pertinent questions throughout. Thank you so much, 
Catherine. Thank you. [Applause] 
Peckham: Thank you all very much. I really enjoyed it.
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Appendix 1
table of British Cohort studies
national survey of 
Health & development 
(nsHd)
1946 This MRC survey collected data from birth of 5362 singleton 
babies born to married parents during one week in March 
in 1946. This was a socially stratified sample taken from initial 
maternity survey of 13 687 births recorded in England, Scotland 
and Wales during that week. Since 1946 the participants have 
been studied 22 times with a change in focus over the years. In 
childhood the emphasis was on the investigation of the effects 
of the home and school environment on physical and mental 
development and educational attainment; during adulthood, this 
emphasis changed to study the relationship between childhood 
health and development and social circumstances and adult 
health and function. More recently, as the cohort reaches 
retirement, the research includes a study of the biological and 
social processes of ageing. See www.nshd.mrc.ac.uk/default.aspx 
(visited 23 January 2012).
national Child 
development study 
(nCds)
1958 This study gathered data from almost 17 500 babies born in 
one week in March 1958 in England, Scotland and Wales. It 
was sponsored by the National Birthday Trust Fund, and was 
designed to examine the social and obstetric factors associated 
with stillbirth and death in early infancy among the children 
born in Great Britain. Since 1958, there have to date been eight 
further sweeps of the members of the birth cohort to monitor 
their physical, educational, social and economic development. 
See www.cls.ioe.ac.uk/page.aspx?&sitesectionid=724&sites
ectiontitle=National+Child+Development+Study (visited 
21 March 2012).
1970 British Cohort 
study (BCs70)
1970 Originally called the British Births Survey (BBS), this study was 
sponsored by the National Birthday Trust Fund in association 
with the Royal College of Obstetricians and Gynaecologists. 
Information was collected about the births and families of just 
under 17 200 babies born in England, Scotland, Wales and 
Northern Ireland in a week in April 1970. Since then there 
have been seven follow-ups to gather information from the 
whole cohort with the emphasis of the study expanding from 
a strictly medical focus at birth, to include physical, educational 
and social development and, more recently, to include economic 
development and other wider factors. See www.cls.ioe.ac.uk/
page.aspx?&sitesectionid=795&sitesectiontitle=Welcome+to+th
e+1970+British+Cohort+Study (visited 21 March 2012).
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Avon Longitudinal study 
of Parents and Children 
(ALsPAC)
1991–2 Originally called The Avon Longitudinal Study of Pregnancy and 
Childhood and also known as Children of the 90s, ALSPAC 
is a long-term health research project, in the former county 
of Avon, which has followed more than 14 000 children due 
between April 1991 and December 1992, from their mothers’ 
pregnancies onwards. Data is collected on health, lifestyle and 
environment as well as biological samples of urine, blood and 
DNA. The vast amount of data has been used to establish 
genetic and environmental determinants of development and 
health. See www.bristol.ac.uk/alspac/ (visited 23 January 2012).
Millennium Cohort  
study (MCs)
2000 Commissioned by the Economic and Social Research Council 
(ESRC), with funding supplemented by a consortium of 
government departments and the Wellcome Trust, this study 
follows the lives of around 19 000 children, selected through 
child benefit records, born in all four UK countries in 2000/1; it 
includes children from disadvantaged social circumstances and 
ethnic minorities. The study covers topics such as parenting, 
childcare, education, behaviour and cognitive development, 
health, social background and ethnicity. Surveys of cohort 
members were carried out at age nine months, three, five and 
seven years; the next is scheduled for 2012.
See http://cls.nemisys2.uk.com/page.aspx?&sitesectionid
=851&sitesectiontitle=Welcome+to+the+Millennium+Cohort
+Study (visited 26 January 2012). 
Birth Cohort study 2012 This study, funded by the Department of Business Innovation 
and Skills (BIS), the Economic and Social Research Council 
(ESRC) and the MRC, will be the largest UK-wide study 
of babies and young children, and will follow over 90 000 
children and their families from pregnancy through to the early 
years. It has been designed to reflect the diversity of ethnic 
identity and social backgrounds and will address important 
issues for children’s health and well-being: for example the 
effects of parenting styles, the influence of eating and physical 
activity behaviours, and the effects of exposure to a range of 
environmental pollutants during early infancy. See, www.esrc.
ac.uk/news-and-events/press-releases/14822/24-million-boost-
to-uks-biggest-study-of-babies-and-young-children.aspx (visited 
23 January 2012).
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Appendix 2
A summary timeline of the origins and development of the  
Avon Longitudinal study of Parents and Children (ALsPAC) for  
the Witness seminar 24 May 2011.
161
1978 Jean Golding (JG) commissioned by DoH to design a 1982 
UK national birth cohort study
1979 National birth cohort for 1982 not funded
1985 JG asked by the World Health Organization to design a 
European set of cohort studies (becomes ELSPAC)
1985 Start of planning and piloting for ALSPAC, one of the 
European cohorts
1988 JG enlists Marcus Pembrey to lead the genetic aspects
1988 Pilot studies for collecting and storing cord blood and 
placentas
1989 ALSPAC Scientific Steering Committee formed
1990 Formation of ALSPAC Ethics and Law Committee 
1990 Start of enrolment of pregnant women and questionnaires 
distributed to parents
1990 Start of storage of maternal blood and urine collected in 
pregnancy
1991 Start of collection of cord blood samples and placentas
1991 December – study goes into the red
1992 First of six monthly examinations of the 10 per cent sample 
‘Children in Focus’ 
1993 The last eligible babies born
1994 Blood for DNA taken at the ‘Children in Focus’ clinic 
1995 Genetic Advisory Committee formed
161 Adapted from a timeline supplied by Professor Jean Golding and distributed at the Witness Seminar.
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1996 Strategic MRC award for DNA-banking
1996 Questionnaire administration to study children
1997 Completion of ‘Children in Focus’ study
1997 Questionnaires to local teachers initiated 
1998 Start of clinical examination and blood for DNA from all 
study children 
1998 First genetics paper (Dunger et al. (1998)) published
2000 DNA bank for 11 000 children and 10 000 mothers 
completed (Jones et al. (2000)) 
2000 Start of nine-year annual examination and blood samples taken 
for cell lines 
2001  Wellcome Trust, MRC, University of Bristol, start (partial) 
core funding, including future generation of EBV-transformed 
cell lines from child and parent samples 
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Appendix 3
funding contributions towards the Children in focus study162
162 Children in Focus. Development and Progress, 3rd edition, June 1997: 89–90. Provided by Mrs Yasmin 
Iles-Caven, and reproduced by permission of Professor Jean Golding. 
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Appendix 4
table of approximate numbers of grants submitted between  
1989 and december 2005163
funder type Awarded failed
Wellcome Trust 41 47
Research councils 23 68
Other charities 60 160
Health authorities 16 39
Commercial sector applications 32 10
UK government 40 58
US government 20 35
EU 3 16
total 235 433 (at least)
163 Table supplied by Mrs Iles-Caven. E-mail to Ms Caroline Overy, 19 September 2011.
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Appendix 5
extract from the Human fertilisation and embryology Bill,  
House of Lords, 1990
164
the Lord Chancellor: … As I indicated in the earlier debate, in many cases 
where infertility treatment is not involved, the information about a child’s father 
on the birth record may not reflect the true genetic position. That can arise for 
a number of reasons; for example, the mother may not know who the child’s 
father is because she was having sexual intercourse with another man as well as 
her husband at the relevant time. After all, the birth register is a record and not 
a legal statement about the reality of who the child’s father is. The noble Lady, 
Lady Saltoun, said that a doctor may ask what one’s father died of. There is a 
chance that if one proceeds on the basis of what is shown on the birth certificate 
one may not give the correct answer. That is one of the problems.
In that connection, the noble Viscount, Lord Craigavon, mentioned the figure 
of 5 per cent. I have had an opportunity to look at that matter more closely. 
It is misleading to believe that at present the information on a birth certificate 
necessarily contains the full facts about the birth of a child. Members of the 
Committee will remember the surprise which greeted the reply made by my 
noble friend Lady Hooper on Second Reading. She indicated that clinical 
geneticists tell us that about one in 20 of today’s population has a father other 
than the one named on the birth certificate. “Wrong paternity”, if I may describe 
it as such, is an important matter to such medical specialists because, for reasons 
that have been outlined, they must take account of it in their clinical practice.
I am not aware of any published research reports from which one can derive with 
certainty an estimate of the prevalence of this state of affairs. But, in an article 
published in Nature on 26th October 1989, mention was made of a figure of 
10 per cent. I have discussed the question with Professor Marcus Pembery [sic], 
Professor of Paediatric Genetics at the Institute of Child Health in London. 
From his experience, he believes that 10 per cent may be a somewhat high 
estimate. In his view, research studies where wrong paternity is an incidental 
164 Human Fertilisation and Embryology Bill [H.L.] Lords Hansard; Column 1317, HL Deb 13 February 
1990 vol 515 c1317–c1318. Contains Parliamentary information licensed under the Open Parliament 
Licence v1.0; http://www.parliament.uk/site-information/copyright/open-parliament-licence/
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finding, and clinical experience of clinical geneticists up and down the country 
each of whom has a service covering a wide geographical area, point to a 
prevalence of at least 5 per cent.
The importance of the matter is stressed in at least one text book and it takes 
up the point that I made in relation to the comment of the noble Lady, Lady 
Saltoun. An article written by Peter Harper, appearing on page 7 of Practical 
Genetic Counselling, 3rd edition, published in 1988, states: ‘Illegitimacy must 
be borne in mind, especially in a puzzling situation. A family doctor or nurse 
may well, particularly in a small community, be able to clarify this possibility. 
Illegitimacy is not of course the problem, but mistaken paternity. New and 
definitive tests of paternity based on DNA will help to resolve those problems 
more easily, but may equally produce new difficulties by the more frequent 
detection of unsuspected non-paternity’. ’1318 A person investigating the 
incidence of a genetic disease may have genetic DNA records of more than one 
generation. It is possible for those who are skilled in the science to tell in some 
instances whether the genetic quality of a child is compatible with the parents. 
The result is that sometimes, quite incidentally and not as part of any deliberate 
study, that is apparent. Of course, if the treatment or diagnosis is based on the 
birth certificate, as is obvious, mistakes can be made. The science of genealogy, 
in so far as it rests on birth certificates, is not on completely secure foundations. 
Nevertheless, it is still an important subject.
The birth certificate as such is not necessarily a correct record of the situation. 
Of course, the birth certificate has always to be understood in the light of the 
existing law. The noble Lord, Lord Henderson of Brompton, referred to the 
kindly presumption of paternity, which exists, and has existed for many years, 
in respect of a child born in wedlock.
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Appendix 6
Letter of instructions for the ALsPAC Air study165
165 Provided by Mrs Ruth Bowles and reproduced with permission of Professor Jean Golding.
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Appendix 7
The Teenage Advisory Panel166
The first meeting of the ALSPAC Teenage Advisory Panel (TAP) was in July 
2006, but this had been preceded for some years by ALSPAC children’s Focus 
Groups. These had been set up and run by the ALSPAC Family Liaison Team 
and were half-day discussion forums, three to four times per year, comprising 
different ALSPAC study children each time, that endeavoured to elicit the 
children’s opinions on a range of subjects.
TAP was initiated by Lynn Molloy, Executive Director of ALSPAC, the Family 
Liaison Team and other members of ALSPAC staff. Initially 25 young study 
participants were recruited from over 200 applicants who had submitted their 
curricula vitarum and their reasons for wanting to take part. The panel were 
chosen to be representative of the cohort by age, gender and social class. They met 
monthly until they were 16 and then once every two months to accommodate 
their busy lives. They also attended several away days and a residential weekend 
plus various training programmes in order to increase their understanding 
and effectiveness. In 2007 TAP elected its own chair and secretary who took 
over from ALSPAC staff who had been fulfilling these functions. In this year a 
dedicated participation worker was appointed to work closely with the panel. 
By 2008 the panel had expanded to 40 study participants.
Members of the ALSPAC Ethics and Law Committee attended TAP 
at the beginning of 2007 to discuss with the young people how they 
could appropriately become involved with ALSPAC’s ethical process. It was 
decided that two representatives from TAP would attend the committee 
whenever possible.
From October 2007, when the first TAP representative attended the ALSPAC 
Ethics and Law Committee, until December 2009, TAP representatives 
attended the committee sporadically (although they were invited to every 
meeting). More frequent representation from TAP would have been useful as 
continuity is important in order to grasp the complexity of the ethical issues 
but it was known that these participants had very busy schedules and lunchtime 
166 This Appendix was written by Professor Gordon Stirrat. E-mail to Ms Caroline Overy, 13 December 2011.
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meetings were difficult for them to attend. Nevertheless the contributions made 
by the representatives were considered extremely useful and frequently provided 
a perspective not necessarily obvious to the committee. On one occasion there 
was some reserved business on the agenda and, since the TAP representative was 
not a full member of the committee, he was informed beforehand that he would 
be asked to leave for this discussion. He, unfortunately, took this personally, and 
was annoyed but when it was explained that this was normal procedure in such 
committees, he accepted it. He was, in fact, a most valuable contributor to the 
meetings! 
During 2009, it was decided that as the participants were reaching the age of 
18, full committee membership for teenage participants would be appropriate. 
Three TAP representatives who had attended the committee, and were based 
locally, were elected to join the committee on the understanding that no more 
than two would attend each meeting. These representatives were considered full 
members of the committee and were treated in the same way as all the other 
committee members. 
key Achievements: 
• Extensive collaboration with lead researchers to advise on content and 
delivery of questionnaires and other mailings. 
• Instrumental in planning the décor and ambience for the two most 
recent clinics and introducing a ‘Big Brother’-style room to enable 
participants attending the clinic to give their views of the study. 
• Substantial ongoing input into the creation of an ALSPAC Facebook 
group – this method of communication is important for keeping in 
touch with the cohort.
• Involvement in the recruitment and interviewing of candidates for the 
posts of participation worker and the data linkage staff for a project 
funded by the Wellcome Trust. 
• Attendance and then full membership of the ALSPAC Ethics and Law 
Committee meetings and representing the study at two ethics symposia.
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Professor (John) david Baum
MD FRCP FRCPH FRCPE 
FMedSci (1940–1999) was 
lecturer, and then clinical reader 
in paediatrics at Oxford University 
from 1972, and in 1977 was 
elected to a professorial fellowship 
at St Catherine’s College. He was 
appointed professor of child health 
at the University of Bristol in 1985 
and from 1988 was a founding 
director of the Institute of Child 
Health (Bristol). He was President 
of the Royal College of Paediatrics 
and Child Health (1997–99). 
Miss karen Birmingham
SRN RMN (b. 1955) is currently 
the research ethics manager 
and ethics archive manager for 
the Avon Study of Parents and 
Children (ALSPAC). She trained 
as a general and psychiatric nurse 
at the London Hospital before 
obtaining a diploma in psychosocial 
and family-centred nursing at the 
Cassel Hospital, Richmond, Surrey. 
She worked clinically, mostly in 
psychiatry, before having two years 
at home as a full-time mother. 
She joined the Department (later 
the Institute) of Child Health, 
Bristol, in 1988 when ALSPAC 
was being planned and piloted. 
She also worked with the Institute’s 
Respiratory Research Group for 
several years. She diverted to 
Pennsylvania for a year when she 
was awarded a scholarship (Quaker 
Studies & Social Change) but 
returned to ALSPAC in 1995 to 
supervise data abstraction from 
medical records and other ALSPAC 
sub-studies. She took over as the 
secretary of the ALSPAC Ethics 
and  Law Committee in 1999. 
She has recently been awarded 
a visiting research post with the 
Swiss Brocher Foundation to write 
a monograph describing the work 
of the Ethics and Law Committee 
during its first 16 years.
Mrs ruth Bowles 
RGN BSc (b. 1960) qualified as 
a state registered nurse at Royal 
United Hospital, Bath, in 1982 
and specialized in intensive care 
nursing following additional studies 
at the Bristol Royal Infirmary 
in 1985. After a brief period as 
sister in the coronary care and 
intensive care unit at Weston 
General Hospital 1987–88 was 
senior sister in Cardiac Intensive 
Care Unit, Bristol Royal Infirmary 
(1988–2010). She completed 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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a BSc (Hons) in information 
technology and computing with 
the Open University (2008) and 
is currently heading the cardiac 
research nursing team at University 
Hospitals Bristol working on a 
portfolio of local, national and 
international cardiology and 
cardiac surgery interventional 
and observational trials. She has 
been a study participant since 
1991 and a study mother member 
of the ALSPAC Law and Ethics 
Committee since 2001.
sir iain Chalmers
Kt FRCP FRGOG FFPH FMedSci 
(b. 1943) has been editor of the 
award-winning James Lind Library 
since 2003. He was director of the 
National Perinatal Epidemiology 
Unit, Oxford, from 1978 to 1992, 
and director of the UK Cochrane 
Centre in Oxford from 1992 
to 2002.
dr ian A f Lister Cheese 
MA PhD FRCP FRCPH (b.1936) 
read natural sciences followed by 
training in research under Walter 
Morgan. He trained in medicine, 
qualifying in 1966. Following posts 
as medical registrar to Sir George 
Pickering and Paul Beeson at the 
Radcliffe Infirmary, he entered 
general practice in Wantage, 
Oxfordshire. There he became a 
tutor in general practice, a trainer 
in the vocational training scheme 
and served in NHS management 
in Oxfordshire. In 1984 he 
joined the senior civil service with 
appointments in the Department 
of Health and the Department 
of Education. His posts included 
responsibilities for the fitness 
of teachers, hospital services for 
children and for genetics services. 
He was secretary to the Standing 
Medical Advisory Committee and 
to the Gene Therapy Advisory 
Committee. He also served on the 
RCP Clinical Genetics Committee 
and committees of the BPA and 
subsequently of the RCPCH, and 
a number of MRC committees.
Following notional retirement in 
1996 he became an adviser to the 
Department of Health on matters 
relating to clinical governance and 
the working of the Abortion Act, 
has undertaken policy work for 
the RCP, the Academy of Medical 
Royal Colleges, and the National 
Director for Health and Work. 
He was a member of the editorial 
board that prepared the first edition 
of the new formulary, Medicines for 
Children. He also served as trustee 
to voluntary bodies concerned with 
the support of disabled children 
and their families.
Professor george davey smith
MA MSc MD FFPHM DSc, 
FRCP FMedSci (b. 1959) has been 
professor of clinical epidemiology 
at the University of Bristol since 
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1994. He is currently scientific 
director of the Avon Longitudinal 
Study of Parents and Children 
(ALSPAC) and director of the 
MRC Centre for Causal Analyses 
in Translational Epidemiology 
(CAiTE). He previously held 
appointments at the University 
of Cardiff, MRC Epidemiology 
Unit, South Wales, University 
College London, London School of 
Hygiene and Tropical Medicine and 
Glasgow University.
Professor Alan emond
MA MD FRCP FRCPCH FHEA 
(b. 1953) is a clinical academic 
paediatrician. He graduated from 
Cambridge University in 1977 
and, since training in internal 
medicine and paediatrics in the UK, 
Jamaica and Australia, he has been 
working in Bristol since 1985. He 
is professor of child health at the 
University of Bristol, head of the 
Centre for Child and Adolescent 
Health in Bristol and consultant 
paediatrician at North Bristol Trust 
and University Hospitals Bristol 
Trust. His clinical background is in 
general and community paediatrics, 
with over 30 years’ experience of 
children’s medicine and child public 
health. His research experience is 
in epidemiology and health service 
evaluation, including work on 
ALSPAC, and in clinical trials. 
He is currently chair of the British 
Paediatric Surveillance Unit. He 
has published widely on child 
growth and development, and has 
advised the English government 
on policy for children. He is an 
experienced educator, with a 
special interest in inter-professional 
teaching and learning. From 
2005–09, he was chair of the British 
Association of Community Child 
Health (BACCH), the national 
organization for community 
paediatricians in the UK. In 2003 
he set up the Centre for Child 
and Adolescent Health in a joint 
initiative between the University 
of Bristol and the University of 
the West of England, creating a 
multi-disciplinary academic group 
undertaking research and teaching 
in community child health.
Professor Jean golding 
OBE, MA, PhD, DSc, FSS, 
MRCPCH, FMedSci (b. 1939) 
graduated in mathematics at 
Oxford in 1961. A career break 
for child care was followed by 
employment 1966–8 by the 
team analysing data from the 
1958 Birth Survey followed 
by a research fellowship at the 
Galton Laboratory, department 
of human genetics and biometry 
to continue the analysis (1968–
1971). Employment at Oxford 
University in Richard Doll’s 
department of the Regius Professor 
of Medicine, and then the National 
Perinatal Epidemiology Unit was 
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then followed by a move to the 
University of Bristol in 1980, to 
the department of child health. 
She won a Wellcome senior 
lecturership in 1982, became a 
reader in 1988 and was appointed 
to a chair in 1992. She founded 
the international journal Paediatric 
and Perinatal Epidemiology in 
1987 and continued as its editor-
in-chief until 2012. She assisted 
in the design and analysis of birth 
surveys in Greece (1983) and 
Jamaica (1986), before creating 
the design and development of the 
ELSPAC and ALSPAC pre-birth 
cohorts; she continued as scientific 
and executive director of ALSPAC 
until the end of 2005. She is now 
emeritus professor of paediatric 
and perinatal epidemiology at the 
University of Bristol where she 
is still research-active. She was 
awarded an OBE for services to 
medical science in the New Year’s 
honours list of 2012.
Professor david gordon
FRCP FMedSci (b. 1947) is a 
general physician. He began his 
academic career in the medical 
unit at St Mary’s Hospital Medical 
School. In a prolonged break from 
his conventional academic medical 
career he was a member of the staff 
of the Wellcome Trust, London, 
responsible for support of biological 
and medical research across a wide 
range of subjects, and for the career 
development of clinical and basic 
biomedical scientists. He worked 
at the University of Manchester 
(1999–2007), most of that time 
as dean of the medical faculty. He 
was chair of the Council of Heads 
of Medical Schools and is also the 
president of the Association of 
Medical Schools in Europe. He 
has been visiting professor at the 
University of Copenhagen since 
2007, in the offices of the World 
Federation for Medical Education.
Mrs yasmin iles-Caven
Dip (Management Studies)
(b. 1962) started working for Jean 
Golding in 1981 after completing 
her A levels, as a clerical assistant. 
From 1982 to 1999 she worked 
as Jean’s personal assistant, and 
was responsible for supervising 
the secretarial team and typing 
mainly research grant applications 
with a growing responsibility for 
ALSPAC finances. In 1999 she was 
promoted to resources manager 
with responsibility for financial, 
personnel and physical resources for 
the Unit of Paediatric & Perinatal 
Epidemiology. In 2003, when the 
faculty underwent restructuring, 
she became departmental manager 
for ALSPAC. She acted as 
secretary to the ALSPAC Steering 
Committee (1999–2004) and 
to the University Management 
Committee. In 2006 ALSPAC 
was moved into the department of 
History of the Avon Longitudinal Study of Parents and Children (ALSPAC), c.1980–2000 – Biographical Notes 
107
social medicine and her job title 
reverted back to resources manager. 
She continued in this capacity until 
December 2010 when she was 
made redundant. She is currently 
assisting Jean Golding with the 
archiving of pre-2005 ALSPAC 
documentation.
dr richard Wynn Jones
DPhil (b. 1943) after a career spent 
in molecular genetic research and 
as a chemical pathologist (MRC 
fellowship and honorary consultant 
in chemical pathology, MRC 
Unit of Molecular Haematology 
and John Radcliffe Hospital, 
Oxford, 1985–1992; senior 
lecturer and honorary consultant 
in chemical pathology, Institute 
of Child Health, University 
of London, 1993–2000), he 
helped to establish and develop 
the ALSPAC laboratory (senior 
research fellow, ALSPAC, 
University of Bristol, 2000–07). 
This laboratory is notable for its 
application of robotic automation 
to DNA-banking and of 
immortalized cell line production. 
Wider responsibilities included 
management of the study’s banks of 
biological samples and liaising with 
research collaborators on the use of 
these resources. 
sir John kingman
Kt FRS MA ScD (b. 1939) studied 
mathematics at the University 
of Cambridge. He was professor 
of mathematics and statistics the 
University of Sussex from 1966 
to 1969 when he was appointed 
professor of mathematics at the 
University of Oxford, a post which 
he held until 1985, when he became 
vice-chancellor of the University of 
Bristol. From 2001 to 2006 he was 
the director of the Isaac Newton 
Institute for Mathematical Sciences, 
during which time he was the first 
N M Rothschild & Sons Professor 
of Mathematical Sciences. He was 
President of the Royal Statistical 
Society (1987–89), and of the 
London Mathematical Society 
(1990–92). He was knighted in 
1985 for his work with the SERC of 
which he was chairman (1981–85). 
Mrs elizabeth Mumford
LLM (b. 1958) was educated at 
Stanford University, the University 
of Toronto and Queens’ College 
Cambridge. She was a lecturer 
in law at King’s College London 
and at Bristol University. She took 
an early ‘retirement’ in 2000 to 
embark on a late career as a mother 
but still lectures on a part-time 
basis in medical law at Bristol.
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Professor Catherine Peckham
CBE MD FMedSci FRCP 
FRCPCH FFPH FRCOG 
FRCPath (b. 1937) is professor of 
paediatric epidemiology and former 
head of the Centre for Paediatric 
Epidemiology and Biostatistics, 
at the Institute of Child Health, 
University College London. She has 
worked on infections in pregnancy 
and the consequences for the child 
and has been closely involved in 
national birth cohort studies. The 
influence of biological, social and 
environmental factors in early life 
on later development has been a 
central theme in her work. She has 
published chapters and papers on 
infections in pregnancy and early 
childhood, the epidemiology of 
common childhood conditions and 
immunisation.
Professor Marcus Pembrey
MD FRCP FRCPCH FRCOG 
FMedSci (b. 1943) trained in 
medical genetics in Liverpool 
(1969–71) and Guy’s Hospital, 
London (1973–78). In 1979 he 
moved to the Institute of Child 
Health, London, as head of the 
Mothercare unit of paediatric 
genetics where he led a team that 
helped to introduce DNA testing 
into clinical genetics in the 1980s. 
He was also consultant clinical 
geneticist at the Hospital for Sick 
Children, Great Ormond Street, 
London (1979–98) and consultant 
adviser in genetics to the Chief 
Medical Officer, Department 
of Health (1989–98). He led 
the genetic component of the 
ALSPAC from 1988. After early 
retirement from the ICH in 1998, 
he continued as director of genetics 
within ALSPAC, University of 
Bristol, until 2006. He continues 
to be visiting professor at the 
University of Bristol. 
Professor Brian Pickering
PhD DSc (b. 1936) is professor 
emeritus in anatomy, University 
of Bristol, and was deputy 
vice-chancellor (1992–2001). 
After a first degree in biological 
chemistry, his research career 
has been concerned with the 
biosynthesis and physiology of 
active polypeptides, principally the 
neuroendocrine products of the 
hypothalamus. After periods in 
the Hormone Research Laboratory 
of the University of California 
(Berkeley), and NIMR, he was at 
Bristol from 1965–2001, being 
head of department of anatomy 
(1978–1992) and dean of the 
faculty of medicine (1985–87). 
He was a founding member of the 
British Neuroendocrine Group 
(British Neuroendocrine Society 
from 2001), serving as its first 
secretary (de-facto chairman), 
(1988–92). He served on AFRC/
BBSRC Animals Research Grants 
Board (1988–94); chairman, 
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(1991–94), on Bristol & Weston 
Health Authority (1988–90) and 
as non-executive director, United 
Bristol Healthcare NHS Trust 
(1990–98).
dr Jon Pollock
PhD (b. 1948) is a reader in 
epidemiology at the University 
of the West of England, Bristol. 
Originally trained as a zoologist 
and physical anthropologist in 
Edinburgh and UCL, he moved to 
Africa to teach postgraduate wildlife 
management and conservation to 
students at the University of Dar 
es Salaam in Tanzania. He spent 
two years managing a conservation 
centre for prosimians at Duke 
University, Durham, North 
Carolina before returning to Bristol 
University, where he was offered the 
opportunity by Professor Golding 
to work there on epidemiological 
studies of child development 
using national cohort study data. 
Drawn into the ALSPAC project 
by Professor Golding’s imaginative 
enthusiasm, he played a small part 
in the early developmental planning 
stages of the project before focusing 
on evaluations of community-
based children’s services at home 
and abroad, with Professor Alan 
Emond. He left Bristol University, 
temporarily, to manage the 
new research department of the 
Royal College of Paediatrics and 
Child Health before returning to 
Bristol to direct the Department 
of Health-funded Research and 
Development Service Unit. He now 
works part-time for its successor, 
the Research Design Service.
dr susan ring 
PhD (b. 1967) is head of the 
ALSPAC Laboratories and a 
member of the current ALSPAC 
Executive Committee. Trained in 
genetics at Sheffield University and 
the Galton Laboratory, UCL, her 
early research interests included 
the genetics and biochemistry 
of blood group antigens and 
red cell membrane proteins. In 
1996 she joined the molecular 
genetics department at Southmead 
Hospital, Bristol to establish the 
DNA bank for the ALSPAC study, 
moving to the University of Bristol 
in 2002 to continue working with 
ALSPAC and the 1958 birth cohort 
establishing cell line banks and 
developing the DNA and biobanks 
for both cohorts. She became head 
of the ALSPAC Laboratories in 
2006.
Mrs sue sadler
BSc Cert Ed (b. 1943) was clinic 
manager at ALSPAC from 1992 
to 2008. After training in Bristol 
she taught biology in secondary 
schools in the Bristol area. After 
the birth of her third child she was 
an antenatal teacher with the NCT 
for ten years. She served on Bristol 
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Community Health Council in the 
1980s and with Maternity Links, 
which provided linkworker support 
for ethnic minority women. 
In September 1990 she joined 
ALSPAC working to recruit women 
from ethnic minorities, coding 
questionnaires, researching data on 
neonatal deaths, writing newsletters 
and liaising with hospitals over 
biological samples. She and Dr 
Jean Golding met with matrons 
of the maternity hospitals, whom 
she knew through NCT work, 
in order to obtain their support 
for the study. She organized the 
measuring of newborn study babies 
in hospital from September 1991 
and the Children in Focus clinics 
from October 1992 for a subset of 
the children, followed by the Focus 
clinics for all participants from age 
seven. She managed these clinics 
until retirement in March 2008.
Professor gordon stirrat 
MA MD FRCOG (b. 1940) is 
emeritus professor of obstetrics & 
gynaecology and research fellow in 
ethics in medicine in the University 
of Bristol. Having trained as an 
obstetrician and gynaecologist in 
Glasgow and London, he became 
clinical reader in the University of 
Oxford in 1975. He was appointed 
professor and head of department 
of obstetrics and gynaecology in 
the University of Bristol in 1982. 
While still holding this post he was 
appointed dean of the faculty of 
medicine (1991–93) and then pro-
vice-chancellor (1993–97). He has 
been a Member of the Southwest 
Regional Health Authority 
(1984–90); the Bristol & Weston 
Health Authority (1990–92) and 
vice-chairman of Bristol & District 
Health Authority (1992–98). He 
served on the General Medical 
Council (1990–93) and was a 
member of the Central Research 
and Development Committee for 
the National Health Service (1990–
94). He was chair of the Ethics 
Committees of the Royal College 
of Obstetricians & Gynaecologists 
(2001–2004) and of ALSPAC 
(2007–10). He is currently a 
member of the Governing Body of 
the Institute of Medical Ethics.
Professor tilli tansey
PhD PhD DSc HonFRCP 
FMedSci (b. 1953) is convenor of 
the History of Twentieth Century 
Medicine Group – known as the 
History of Modern Biomedicine 
Research Group from 2010 –  and 
professor of the history of modern 
medical sciences at Queen Mary, 
University of London.
dr Linda tyfield
MSc PhD FRCPath (b. 1946) 
was a consultant clinical scientist 
and head of molecular genetics 
at Southmead Hospital, Bristol. 
After studying nutrition and 
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biochemistry at the University of 
Toronto and Bristol University she 
specialized in the biochemical study 
of inherited metabolic disease at the 
clinical biochemistry department 
at Southmead Hospital. In 1988 
she set up a molecular genetics 
unit there specializing in the 
genetic analysis of neurological 
and muscular diseases and later 
became head of the department of 
molecular genetics. Her research 
interests were in genetic variation in 
inherited metabolic disease, genetic 
variation within and between 
populations and genetic changes 
in neurological tumours. The 
extraction of DNA from samples 
collected for the ALSPAC cohort 
was originally developed and tested 
in her department. She has had 
many research collaborations with 
colleagues in Europe and North 
America. She was chairman of 
the Clinical Molecular Genetics 
Society from 2000 to 2004 and has 
served on many professional and 
government advisory committees. 
Mr Mike Wall
DipLib MCLIP (b. 1965), a 
study father, has been head of 
information management at the 
University of Bristol since 2007. 
He has recently gained funding 
to scope and then deposit the 
ALSPAC archive at the University 
of Bristol Library. 
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Action Research (Action Medical 
Research from 2003), 15, 64
air pollutants, 13, 16
air study, ALSPAC, 40, 91–2
anaesthetic cream, 51, 52, 53, 54
anonymity of data, 35, 48, 73–4
anticoagulant, blood samples, 63
ARIES project, 51
Asian languages, materials in, 28, 
29, 31
Asthma UK (formerly National 
Asthma Campaign), 15, 47
Athens, 11, 57
autonomy, 35
Avon Longitudinal Study of Parents 
and Children (ALSPAC), 82
enlistment of researchers, 8–10, 
11–12
Ethics Committee see Ethics and 
Law Committee
origins, 4–12, 13–14
restriction to local area, 12–13
timeline, 83–4
Avon Preterm Follow-up Study, 12
barcodes, 61, 62, 63
Biobank, UK, 36, 71
biological samples see samples, 
biological
Biotechnology and Biological  
Sciences Research Council 
(BBSRC), 51
birth certificates, 37–8, 89, 90
birth cohort studies, 3–4, 5, 13–14, 
81–2
access to data, 69
Birth Cohort study, 1958 see National 
Child Development Study
Birth Cohort Study 2012, 14, 32, 82
blood pressure, measurement, 13, 49
blood samples, 38
anticoagulant, 63
cell lines from, 20, 50
from children, 51–7
collection systems, 53
DNA extraction, 61, 62–3
duplicates, 68
ethical approval, 52, 55–7, 68, 78
from fathers, 37
from mothers, 27, 42–3, 56
new technologies for analysing, 68–9
storage, 43
see also cord blood samples
bone scans, 40, 41
breast milk, 38
Bristol
ALSPAC research team, 5, 8–9
genetics services, 59, 60–1
study localisation, 13, 27, 47
Bristol Children’s Hospital, 60–1
Bristol Maternity Hospital (now St 
Michael’s), 27
Bristol University
financial support, xxi, 9, 17–19, 
22–3, 70
genetics department, 59
research ethics committee, 36
British Cohort Study, 1970 (BCS70), 
13, 14, 81
British Paediatric Association (BPA) 
(Royal College of Paediatrics and 
Child Health from 1996), 52, 
55, 72
cannabis, 47–8
cell lines, 20–1, 50, 58, 62
charities, funding by, 15–16, 23, 85, 87
check digits, 60, 67
Index: Subject 
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Chief Medical Officer (CMO), 33, 38
child abuse, potential, 77
children
blood sample collection, 51–7
consent by, 55–7
educational choices of 
participating, 42
ethics of research using, 52, 55–7, 58
examination, 13
looking after participating, 39–42
safeguarding concerns, 77
sample types collected, 52
Children in Focus clinics, 23
blood sample collection, 51–7, 78
free gifts, 23
funding, 22, 85
involvement of participants, 40, 41
samples for DNA analysis, 59
staff recruitment, 25
‘Children of the 90s’ see Avon 
Longitudinal Study of Parents and 
Children
Christchurch Health and Development 
Study, New Zealand, 47
clinical genetics, 59, 60
coefficients of variation 
    DNA samples, 68
cohort studies, 3–8, 81–2
local, 12–13
national, 3–4, 5, 13–15, 81–2
collaborators, research
access to data, 66–7, 69–70
availability of DNA samples, 61, 63, 
64–8
requests for payments from, 66, 
69–70
community, local see local community, 
involvement
computer team, ALSPAC, 60–1, 67
computing facilities, funding, 68
confidentiality, 35, 73
congenital malformations, 5
consent, 73
by children, 55–7
DNA studies, 46, 58, 59
longitudinal studies, 39
sample collection and analysis, 44, 
48–9, 73
cord blood samples, 38
collection, 42–3, 44, 49–50, 56
DNA analysis, 50–1, 63
documentation, 45
immortalized cell lines, 20, 50
cosmetic companies, sale of placentas 
to, 45–6
cross-sectional studies, 14
cytomegalovirus (CMV), 3, 49
Czech Republic, 7
data
access of collaborators to, 66–7, 
69–70
access of participants to own, 
35–6, 74
anonymity, 35, 48, 73–4
linkage see record linkage
see also genetic information
data analysis
cohort studies, 4
funding, 45, 68
data collection
funding, 70
obstetric case notes, 44–5
defensive medicine, 72
Department of Child Health, 
Bristol, 17
Department of Health (DoH), 5, 15, 
19, 21, 33
Department of the Environment (part 
of Defra since 2001), 12, 16
DNA
availability to collaborators, 61, 63, 
64–8
bank, 58, 62–4
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charging for samples, 66
degradation during storage, 61, 62
extraction, 59, 60, 61, 62–3
maternal vs child, 51
methylation, 57, 66
paternity testing, 90
quantitation, 64–5
DNA studies, 57–69
consent for, 46, 58, 59
cord blood samples, 50–1
duplicate samples, 68
ethical approval, 75–6
funding, 21, 58, 59, 63–4, 68, 69
see also genetics
duplicate blood samples, 68
Economic and Social Data Service 
(ESDS), 69
Economic and Social Research Council 
(ESRC), 14, 70, 82
EDTA (ethylenediaminetetraacetic 
acid), 63
electric magnetic radiation, 13
EMLA (Eutectic Mixture of Local 
Anesthetics) cream, 52, 53, 54
environmental exposure, measuring, 5, 
7, 12–13
epidemiological research, xxii–xxiii
epigenetic studies, 50–1, 57, 66
Ethics and Law Committee, ALSPAC, 
xxii, 33–6, 71–8
blood collection from children, 52, 
55–7
chairmen, 74, 75
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